Conservative Management vs. Dialysis
Most patients are offered a choice between types of dialysis — not a choice about whether to start dialysis at all. That is a consent problem, not a clinical inevitability.
What you're typically told
"Your kidneys are failing. You need dialysis."
What you're rarely told
For certain patients — particularly older adults with significant comorbidities — conservative kidney management may offer comparable survival with substantially better quality of life.
What the research suggests
The survival picture is more complicated than it appears
Murtagh et al., 2007 — Nephrology Dialysis Transplantation
In patients over 75 with significant comorbidity, survival with conservative kidney management (CKM) was not significantly different from dialysis. Median survival was 13 months with CKM versus 21 months with dialysis — but dialysis patients spent a greater proportion of that time in a medical facility.
Tamura et al., 2009 — New England Journal of Medicine
Among nursing home residents who initiated dialysis, 58% died within the first year. Of those who survived, 70% experienced significant functional decline during the first year on dialysis — meaning the majority who lived did not regain their previous level of function.
Verberne et al., 2016 — American Journal of Kidney Diseases
In elderly patients with eGFR below 15 and high comorbidity burden, dialysis added approximately 1.4 years of median survival. However, conservative management preserved functional independence and time spent at home for a longer proportion of remaining life.
SELECT Data, 2022
Reinforced that the decision to initiate dialysis depends heavily on individual comorbidity burden — not just on GFR number. The kidney function lab value alone does not determine benefit.
Critical distinction
Conservative kidney management is not "doing nothing"
CKM is an active, structured medical program. It typically includes:
- →Ongoing nephrology follow-up and monitoring
- →Symptom management (fluid balance, anemia, fatigue, pain)
- →Dietary support with a renal dietitian
- →Fluid management and electrolyte monitoring
- →Palliative care coordination and advance care planning
- →Quality-of-life-centered decision-making at each stage
When dialysis does make a meaningful difference
Dialysis is not without benefit — context determines benefit
The research does not argue against dialysis. It argues for honest, individualized conversations. Dialysis is most clearly beneficial when:
- 1The patient is younger and otherwise in relatively good health (single-organ failure without significant comorbidity)
- 2The patient is a realistic transplant candidate and dialysis serves as a bridge to transplantation
- 3Kidney failure is acute or reversible, not end-stage progressive disease
- 4The patient has a clear understanding of what dialysis requires and has chosen it with full information
The consent problem
Most patients are not offered CKM as a formal option
The standard clinical conversation is typically structured around which type of dialysis — hemodialysis vs. peritoneal dialysis, home vs. center-based. The question of whether to initiate dialysis at all, including conservative management as a named alternative with an honest comparison of outcomes, is frequently absent from that conversation. This is not informed consent. You are entitled to ask explicitly: "What are my options, including the option of not starting dialysis?"
What patients are rarely told
You can stop — and approximately 1 in 5 dialysis patients do
What patients are typically told
"If you stop dialysis, you will die."
This is technically true. What it omits is everything that makes the choice meaningful.
What is also true
The right to stop dialysis is legally protected, ethically established, and exercised by roughly 20–25% of dialysis patients — approximately 1 in 5 dialysis deaths in the US is preceded by the patient's decision to stop treatment.
The other 4 in 5 die of: cardiovascular disease (~40–45%), infection and sepsis — most of it access-related (~10–12%), malignancy (~5–8%), and other causes. Dialysis is a direct contributing factor to most of these deaths: it accelerates cardiovascular disease through hemodynamic stress and vascular calcification; it is the source of most infections through catheter and graft bacteremia; and the uremic toxins it only partially clears create a chronic pro-inflammatory, pro-carcinogenic environment. The mortality is on dialysis, not simply despite it.
Scenario 1 — Acute dialysis, started as a bridge
Dialysis is sometimes started during an acute kidney injury — a sudden, potentially reversible drop in kidney function caused by illness, surgery, medication, or dehydration. In these cases dialysis is a bridge, not a permanent commitment. If the underlying cause resolves, dialysis can be stopped and the kidneys may partially or fully recover. Patients in this category are entitled to know from the beginning whether their situation is acute or chronic, and what the realistic probability of kidney recovery is. That distinction changes the entire informed consent conversation.
Scenario 2 — End-stage renal disease: the right to withdraw
For patients with true ESRD — permanent, irreversible kidney failure — stopping dialysis is a terminal decision. The legal and ethical right to make it is well established. It is not suicide. It is withdrawal of a life-sustaining treatment, a right that applies to any patient for any treatment under settled medical ethics and law.
According to USRDS data, approximately 21% of all deaths in dialysis patients are preceded by the patient's decision to stop treatment. This is one of the most common ways dialysis ends — and it is almost never named as an option in the initial informed consent process.
What stopping looks like — the clinical picture
For a patient with no residual kidney function, death typically occurs within 7 to 14 days after dialysis is stopped — median approximately 8 to 10 days. Patients with some remaining kidney function may survive for several weeks.
The causes of death are uremia (accumulation of waste products the kidneys can no longer clear) and hyperkalemia (dangerously elevated potassium affecting heart rhythm). Hospice and palliative care can manage the symptoms of this process: morphine for air hunger and dyspnea, anxiolytics for anxiety, symptom management for discomfort. Uremia itself, as it progresses, produces increasing drowsiness and confusion before unconsciousness — it is not typically a painful death when appropriately managed.
This is information patients are entitled to have — not to be pushed toward stopping, but because the decision to continue dialysis indefinitely should be a genuine informed choice, not the only option that was ever fully explained.
The consent gap: Many patients report that they were never told stopping was an option. Some report being told that stopping "isn't allowed" or that "nothing can be done to make it comfortable." Neither is accurate. If you are considering stopping dialysis — or want to understand your options — you are entitled to a formal palliative care consultation, an honest conversation about prognosis with and without dialysis, and access to hospice evaluation if appropriate. You do not need your dialysis team's permission to pursue any of these.
USRDS — U.S. Renal Data System, Annual Reports
The explosion in dialysis
Americans receiving dialysis for end-stage renal disease (ESRD), 1973–2022. In 1972, Congress passed the Social Security Amendments that created the Medicare ESRD benefit — making dialysis the only condition-specific Medicare entitlement, available to any American regardless of age or work history. The industry that followed grew accordingly.
Sources: USRDS 2023 Annual Data Report · FTC & academic literature on dialysis market concentration · Medicare ESRD history: Social Security Amendments of 1972, Pub. L. 92-603
Questions you are entitled to ask
Before deciding
"What is my expected survival on dialysis versus conservative management, given my specific age and comorbidities?"
Not a general statistic — your specific situation, including heart disease, diabetes, mobility, and functional status.
"How much of that additional time would I spend in a dialysis center versus at home?"
Time in facility versus functional time at home is a quality-of-life question the data supports asking.
"What does a typical week look like on dialysis for someone with my health profile?"
Not a general description — specific to your current functional status and trajectory.
"Am I a transplant candidate? What is the realistic wait time at this center?"
If transplant is not realistic, the calculus for enduring years of dialysis changes significantly.
"What does conservative kidney management include, and who provides it?"
You are entitled to this option explained clearly, not dismissed.
Life on Dialysis: The Full Picture
Dialysis keeps people alive. It also restructures every dimension of daily life — permanently, and without exception. This is the information that should accompany the prescription.
Time commitment
12 to 15+ hours every week, indefinitely
Center-based hemodialysis requires three sessions per week, each lasting three to five hours, plus travel time to and from the center and recovery time afterward. The total time commitment is typically 12 to 15 or more hours per week — every week, for as long as the patient is on dialysis.
Missing sessions is not optional. Even a single missed treatment causes rapid accumulation of fluid and electrolytes that becomes a medical emergency. There is no flexibility built into this schedule in the way there is with most medications or treatments.
A month mapped out
What your calendar looks like — for the rest of your life
Standard center hemodialysis: Monday / Wednesday / Friday. Four weeks shown. Every single day includes fluid restriction and dietary management — those constraints do not appear on the calendar because they never turn off.
In a 28-day month: 12 days spent in a dialysis center · 12 days of significant post-treatment fatigue · 4 Sundays with minimal dialysis-specific obligation. This is the schedule indefinitely — or until a transplant. Employment, travel, family obligations, and spontaneity all reorganize around the machine.
One of the most underreported effects
Post-dialysis fatigue: "The dialysis hangover"
60 to 70% of patients report significant fatigue lasting 6 to 14 hours after each dialysis session. Many patients describe "writing off" the rest of the day following treatment. This occurs three times per week. It is one of the most significant quality-of-life impacts on dialysis, and it is rarely mentioned before treatment begins. No effective intervention exists — it is a consequence of the treatment itself.
Fluid restriction
32 oz per day — total
Approximately one liter of fluid per day, including water in food. In summer heat, thirst becomes a significant and constant quality-of-life issue. Fluid overload between sessions causes pulmonary edema, hypertension, and cardiovascular stress — which is why the restriction cannot be loosened.
Dietary restrictions
Permanent and significant
Low potassium: no bananas, oranges, tomatoes, or standard potatoes. Low phosphorus: limits dairy, nuts, whole grains, beans, and dark colas. Sodium restriction. Protein is complicated — high enough to prevent muscle wasting, low enough not to overload a system that can no longer clear nitrogen waste efficiently.
Occurring in 20–30% of all treatments
Intradialytic hypotension (IDH)
Blood pressure drops during dialysis sessions in 20 to 30% of treatments. Symptoms include cramping, lightheadedness, nausea, and vomiting. In serious cases, IDH reduces blood flow to the heart and brain during a session.
Long-term consequence
Repeated intradialytic hypotension events are associated with myocardial stunning — transient regional dysfunction of the heart muscle that accumulates with each episode — and with accelerated cognitive decline. These consequences are largely invisible in real time.
Leading cause of death in dialysis patients
Cardiovascular mortality: 10 to 30 times the general population rate
Dialysis patients die of cardiovascular disease at 10 to 30 times the rate of the general population, adjusted for age and diabetes. Each hemodialysis session creates significant hemodynamic stress on the heart. The treatment that keeps the patient alive simultaneously stresses the organ most likely to cause death. This is not a reason to refuse dialysis — it is information that belongs in the informed consent conversation.
Sleep disruption
Restless legs and sleep apnea
Restless leg syndrome and sleep apnea occur at dramatically higher rates in end-stage renal disease than in the general population. Sleep disorders compound fatigue and further increase cardiovascular risk — creating a reinforcing cycle that is difficult to interrupt.
Employment and travel
Life organized around the center
Center-based hemodialysis requires proximity to a dialysis facility. International travel requires advance coordination of center access at the destination — sometimes weeks in advance. Employment rates drop significantly after dialysis initiation, reflecting both the time burden and the physical toll of treatment.
What patients are not told
The pain — and the simple things that help
Pain is one of the most significant and least-discussed realities of life on dialysis. Patients are frequently told the treatment will keep them alive. They are rarely told how much it will hurt — or that inexpensive, accessible interventions exist for much of it that are almost never offered.
Intradialytic muscle cramps — during treatment
Severe muscle cramps during dialysis sessions affect 20 to 70% of patients depending on the study. The cause is rapid fluid and electrolyte removal — particularly magnesium, which the dialysis process actively removes every session. Cramps can be severe enough to cause patients to cut sessions short, which worsens outcomes. They are normalized by dialysis staff as an expected side effect of treatment.
What patients aren't told
Topical magnesium chloride — often called magnesium oil — applied directly to cramping muscle before, during, or after treatment can provide rapid relief. Transdermal absorption bypasses the gut entirely, which matters because oral magnesium supplementation is restricted in CKD/dialysis patients due to impaired renal excretion. Topical application delivers magnesium to the muscle locally without the systemic load of oral dosing. It is inexpensive and available without a prescription. It is almost never mentioned.
Magnesium depletion — the root cause no one names
Dialysis removes magnesium every session. The typical dialysate (the fluid used in hemodialysis) contains lower magnesium concentrations than healthy blood — so net magnesium moves out of the patient's body into the drain at every treatment. On top of this, PPIs (extremely common in dialysis patients), diuretics, and several other medications on the standard dialysis drug list independently deplete magnesium. The result is a population with pervasive, chronic, undertreated magnesium deficiency — and the symptoms that follow: muscle cramping, restless legs, difficulty sleeping, headaches, increased anxiety, and worsened bone pain.
Standard serum magnesium labs frequently appear normal even when intracellular magnesium is low — because the body maintains serum levels by pulling from bone and muscle stores. A normal lab result does not mean adequate magnesium status.
What patients aren't told
Topical magnesium chloride (applied to skin — feet, legs, forearms) is an accessible way to replenish magnesium without adding to oral pill burden or triggering the hypermagnesemia risk of oral supplementation in low-GFR patients. Dialysate magnesium concentration can also be adjusted by the treating nephrologist — some centers use higher magnesium dialysate specifically to reduce cramping. Patients are rarely told this is a variable that can be changed.
Restless legs syndrome — nightly, indefinitely
Restless leg syndrome (RLS) — an uncontrollable urge to move the legs, typically worsening at night, accompanied by uncomfortable crawling or burning sensations — affects an estimated 20 to 60% of dialysis patients, compared to about 5–10% of the general population. It destroys sleep. In the context of already severe fatigue from treatment itself, nightly RLS creates a cycle of exhaustion that compounds every other symptom the patient is managing. The pharmaceutical treatment offered is typically dopamine agonists — medications with significant side effects including compulsive behaviors and worsening RLS with long-term use (augmentation).
What patients aren't told
RLS has a strong association with magnesium and iron deficiency — both of which are pervasive in dialysis patients. Topical magnesium chloride applied to the legs before bed has helped many patients reduce RLS severity. Adequate iron repletion (assessed properly with a full iron panel — not ferritin alone) is also a known modifier. These are cheap, low-risk interventions that are not routinely offered before moving to dopamine agonists.
Needle cannulation pain — three times a week, every week
Center-based hemodialysis requires insertion of two large-bore needles into the fistula or graft at every session — 312 needles per year. For many patients this is painful, anxiety-provoking, and dreaded. The pain of needle cannulation is frequently dismissed by staff who have performed the procedure thousands of times. Patients who say it hurts are sometimes told it should not hurt, or that they need to tolerate it. This is not acceptable — and it is not necessary.
What patients aren't told
EMLA cream (lidocaine/prilocaine topical anesthetic) applied to the fistula site 60–90 minutes before needling provides effective numbing. It is available by prescription and at some centers is provided routinely — but many patients go years without being told it exists. A warm towel applied to the site before cannulation can also dilate the vessel and reduce procedural pain. Buttonhole cannulation technique (using the same track repeatedly to create a tunnel) is less painful than rotating rope-ladder technique for many patients — and patients can ask specifically which technique their center uses and whether they can request a different approach.
Post-dialysis headache and general aching
Headaches after dialysis are common — caused by rapid shifts in fluid, solutes, and blood pressure during and after the session (dialysis disequilibrium). Combined with the general aching and malaise of post-treatment fatigue, many patients describe feeling physically beaten after every session.
What patients aren't told
Headache frequency and severity can often be reduced by slowing the ultrafiltration rate — the speed at which fluid is removed during the session. This is a programmable variable. Patients are entitled to ask their care team whether their ultrafiltration rate can be adjusted to reduce post-treatment symptoms. Cooler dialysate temperature has also been shown to reduce intradialytic hypotension and its downstream symptoms, including headache. These are adjustable clinical variables — not fixed features of the treatment — and patients who are suffering are entitled to have the conversation about adjusting them.
Bone and joint pain
Renal osteodystrophy and secondary hyperparathyroidism produce aching, deep bone pain — particularly in the lower back, hips, and legs. This is chronic and progressive if the underlying mineral metabolism is not well-managed. It is also contributed to by the systemic inflammation and magnesium deficiency already present.
What patients aren't told
Magnesium is a cofactor in bone mineralization and a natural calcium antagonist — magnesium deficiency worsens bone pain and contributes to the calcification patterns underlying much of this discomfort. Topical magnesium chloride applied to painful areas can provide localized relief. The choice of phosphate binder also matters: non-calcium binders (sevelamer, lanthanum) avoid adding to the calcification burden that calcium carbonate binders contribute to. Patients rarely know they can ask to switch binder types — or that the binder being given to them is worsening their vascular calcification.
The pain of dialysis is real. It is not a sign that something has gone wrong — it is a predictable consequence of the treatment itself and the conditions that accompany it. What has gone wrong is that patients enter this process without being told what to expect, and without being offered the simple, low-cost interventions that could meaningfully reduce their suffering. Magnesium chloride topically. EMLA cream before needling. Ultrafiltration rate adjustment. Dialysate temperature. Buttonhole cannulation. None of these require a prescription battle or a specialist referral. They require someone to mention that they exist.
What survival actually looks like over time
The ten-year picture — alive, but at what cost
Survival statistics count anyone who is still living. They do not capture what that living looks like. The patients who survive ten or more years on dialysis have typically accumulated a set of complications that are rarely named in the initial informed consent conversation — and that compound one another progressively over time.
Non-healing wounds
Even on dialysis, uremic toxins persist — standard hemodialysis removes approximately 15–20% of what healthy kidneys clear. This residual uremic environment impairs collagen synthesis, immune function, and tissue oxygenation, producing wound healing failure that would be considered abnormal in any other patient. Calciphylaxis — calcium crystal deposition in the walls of small blood vessels — causes excruciatingly painful, non-healing ulcers on the abdomen, thighs, and breasts. It is almost exclusive to dialysis patients and carries a one-year mortality of 45–80%. Peripheral arterial disease accelerates in the presence of accelerated vascular calcification, producing ulcers on the feet and lower legs that will not close.
Amputations
Dialysis patients undergo lower extremity amputations at a rate 10 to 30 times that of the general population. The combination of diabetic peripheral neuropathy (the most common cause of ESRD), accelerated vascular calcification, wound healing failure, and increased infection susceptibility creates an environment where minor foot injuries progress to gangrene. After a first amputation, the risk of a second is high. Many long-term dialysis patients end up with bilateral amputations — changes that are permanent and that permanently alter every dimension of their physical life, independence, and care requirements.
Erectile dysfunction
Studies report erectile dysfunction in 70 to 80% of men on hemodialysis — one of the highest prevalence rates of any chronic disease population. The mechanisms are multiple and overlapping: autonomic neuropathy, vascular calcification reducing penile perfusion, suppressed testosterone production in the uremic environment, anemia reducing oxygen delivery, depression, and the antihypertensive medications required by most dialysis patients. Testosterone levels are frequently significantly below normal in men with ESRD. This is almost never raised in the informed consent process — yet for many men, it is one of the most significant quality-of-life impacts they experience.
Cognitive decline
Each intradialytic hypotension event — occurring in 20 to 30% of all sessions — causes transient cerebral hypoperfusion. Over years of three-times-weekly treatment, these events accumulate. Dialysis patients have significantly higher rates of dementia and cognitive impairment than age-matched controls. The term "dialysis dementia" was historically used to describe a specific aluminum-related encephalopathy; the broader pattern of accelerating cognitive decline in long-term dialysis patients is now understood to involve cumulative ischemic injury, uremic neurotoxicity, and chronic cerebral underperfusion compounding one another.
Bone disease and fractures
Renal osteodystrophy — the bone disease of chronic kidney failure — encompasses secondary hyperparathyroidism, adynamic bone disease, and osteomalacia. The disruption of phosphorus, calcium, and parathyroid hormone regulation that begins in CKD continues and often worsens on dialysis. Long-term dialysis patients have dramatically elevated fracture risk. Fractures in this population carry high mortality; hip fracture in a dialysis patient is a life-limiting event with one-year mortality rates exceeding 50% in some studies.
Severe itching (uremic pruritus) and skin changes
Up to 40% of dialysis patients experience chronic uremic pruritus — intense, persistent itching caused by phosphate deposits, uremic toxins, and mast cell activation in the skin. For many patients, this is among the most debilitating symptoms they live with. Scratching produces excoriations that become infected given the immune dysfunction already present. Sleep is disrupted. Quality of life scores for patients with severe uremic pruritus are among the lowest recorded in any disease population.
Progressive muscle loss and loss of independence
Protein-energy wasting — a condition of simultaneous protein depletion and inflammation distinct from simple malnutrition — affects 18 to 75% of dialysis patients depending on criteria used. The dialysis procedure itself causes amino acid losses. The dietary restrictions required complicate adequate protein intake. The result over years is progressive sarcopenia (muscle mass loss), weakness, and loss of physical independence. Those who could walk into the dialysis center independently in year one may require wheelchair transport by year five.
These complications are not rare outcomes. They are the statistically expected trajectory for a significant proportion of people who survive a decade on dialysis. They represent the part of the survival statistics that the survival statistics do not show. Whether that trajectory is acceptable — and what alternatives exist — is a conversation that belongs before starting, not after years have passed.
What almost no one is told before starting dialysis
Calciphylaxis
Calciphylaxis is one of the most serious and least-disclosed complications of long-term dialysis. It occurs almost exclusively in this population. One-year mortality is 45 to 80%. It is rarely mentioned before dialysis begins.
What it is
Calciphylaxis — also called calcific uremic arteriolopathy (CUA) — is the deposition of calcium crystals in the walls of small blood vessels in the skin and subcutaneous tissue. As the calcium deposits accumulate, the vessel walls calcify and narrow, cutting off blood supply to the tissue they feed. The tissue dies from the inside.
The result is excruciatingly painful skin lesions — typically on the abdomen, thighs, buttocks, and breasts — that begin as livedo reticularis (mottled purple skin patterning) and progress to deep, necrotic, non-healing wounds. These wounds do not close because the blood vessels supplying the tissue have been destroyed. The pain is severe and continuous. Standard wound dressings do not help. Standard pain management is inadequate in many cases.
One-year mortality: 45–80% depending on wound location, infection complications, and degree of metabolic derangement. Truncal lesions carry higher mortality than peripheral lesions. Death is typically from sepsis originating in the wounds, or from cardiovascular collapse.
Who gets it — the risk factors that are within clinical control
This is not a random complication — it is driven by modifiable inputs
Calciphylaxis requires three converging conditions: (1) the uremic environment of dialysis, which disrupts calcium-phosphate regulation at the cellular level; (2) chronic calcium loading — from calcium-based phosphate binders and activated vitamin D analogs — that deposits excess calcium where it doesn't belong; and (3) impaired clearance of calcium from small vessels, driven by inflammation and vascular wall injury. All three are present in most long-term dialysis patients, and all three are influenced by clinical choices made before calciphylaxis appears.
Calcium-based phosphate binders — PhosLo, Tums used off-label, calcium carbonate
Every dose of a calcium-based phosphate binder delivers a calcium load to a system that cannot regulate calcium normally. In the dialysis population, this calcium goes directly into a vascular wall environment already primed for calcification. Research consistently shows that calcium-based binders accelerate coronary artery calcification, aortic calcification, and — in susceptible individuals — the small-vessel calcification of calciphylaxis. Non-calcium binders (sevelamer, lanthanum carbonate) do not carry this risk. The choice of binder is a clinical decision. It is rarely explained as one that affects calciphylaxis risk — or vascular calcification risk — before the prescription is written.
Activated vitamin D analogs — calcitriol, paricalcitol, doxercalciferol
Activated vitamin D analogs increase intestinal calcium absorption and can produce hypercalcemia — particularly when prescribed alongside calcium-based phosphate binders. Hypercalcemia in the dialysis setting does not simply produce elevated blood calcium readings. It drives calcium-phosphate product elevation (Ca × PO₄) in vessel walls, where crystal nucleation begins. The combination of calcium-based binders + activated vitamin D analog + the pro-calcifying uremic environment creates the conditions for calciphylaxis in susceptible individuals. Monitoring calcium closely when both are prescribed is standard recommendation — but the cumulative vascular calcification trajectory from years of this combination is rarely explained at the outset.
Warfarin — a frequently overlooked calciphylaxis driver
Warfarin blocks vitamin K-dependent carboxylation of Matrix Gla Protein (MGP) — the primary endogenous inhibitor of vascular calcification. MGP requires vitamin K2 to become active; without it, MGP sits in vessel walls in its inactive form and cannot prevent calcium crystal deposition. Warfarin essentially disarms the body's own anti-calcification defense in the very tissue where calciphylaxis develops. Multiple studies document significantly higher calciphylaxis rates in dialysis patients on warfarin compared to those on other anticoagulants. Warfarin is commonly prescribed for atrial fibrillation, hypercoagulable states, and deep vein thrombosis in dialysis patients — all common comorbidities. The calciphylaxis risk from warfarin in this population is documented and significant. It is almost never disclosed when the anticoagulation conversation happens.
Obesity, diabetes, female sex, and elevated calcium-phosphate product
Epidemiological data identifies obesity, diabetes, and female sex as independent calciphylaxis risk factors, in addition to elevated calcium-phosphate product, elevated parathyroid hormone, hypoalbuminemia, and iron infusion history. The convergence of these risk factors is common in long-term dialysis patients — meaning a large proportion of those on dialysis carry clinically significant calciphylaxis risk without knowing it and without having been counseled about the modifiable elements of that risk.
What calciphylaxis pain actually looks like — what patients are not told
The pain of active calciphylaxis is among the most severe documented in medicine. It is described as deep, burning, unrelenting, and poorly controlled by standard analgesics. Opioid requirements in calciphylaxis patients are often substantial. The wounds that develop — necrotic, wet, malodorous, and non-healing — require specialized wound care that dialysis centers are not equipped to provide. Many people with calciphylaxis require inpatient hospitalization for wound management, but wound closure is often impossible because the blood supply to the affected tissue has been destroyed.
Sodium thiosulfate — an inorganic compound used industrially and as a cyanide antidote — has become the primary treatment for calciphylaxis, given intravenously during dialysis sessions. It works by chelating calcium deposits and dissolving calcifications in vessel walls. It is not FDA-approved for this indication; it is used off-label based on accumulated case series data. Pain typically does not resolve until calcification begins to regress — a process that takes weeks to months, if it occurs at all.
The information gap: None of this is typically communicated before dialysis begins. People are not told that years of calcium-based phosphate binders combined with warfarin and activated vitamin D analogs create a documented pathway to this condition. They are not told that if they develop it, wound closure may be impossible and pain control inadequate. They are not told that switching from calcium-based to non-calcium binders — a simple prescription change — reduces this risk. They are not told that warfarin may not be the right anticoagulant for them specifically because of this risk. These are conversations that belong before dialysis-associated calciphylaxis treatment is initiated — not after the wounds have appeared.
The questions to ask — before calciphylaxis happens
"Am I on a calcium-based phosphate binder, and would switching to sevelamer or lanthanum reduce my vascular calcification risk?"
This is a prescribable change. Non-calcium binders cost more but do not carry the calcification burden of calcium carbonate binders.
"If I am on warfarin, has my calciphylaxis risk been specifically assessed, and are there alternative anticoagulants that do not block Matrix Gla Protein?"
Direct oral anticoagulants (DOACs) do not share warfarin's anti-MGP mechanism. Whether they are appropriate depends on the specific indication for anticoagulation.
"What is my calcium-phosphate product, and what is the calcification trajectory given my current medications?"
Ca × PO₄ above 55 mg²/dL² is the threshold above which calcification accelerates. This is a trackable number — and one that should be discussed, not just documented.
Medications & Side Effects
Dialysis involves a standard medication regimen that most patients receive without a full explanation of mechanism, risks, or alternatives. These are the things that belong in the conversation.
CKD Anemia — The Distinction Almost Never Explained
This is not iron deficiency anemia
In healthy kidneys, cells that sense low oxygen signal the kidney to produce erythropoietin (EPO), which instructs the bone marrow to make red blood cells. In chronic kidney disease, this signaling pathway is broken — the kidneys cannot produce sufficient EPO. The bone marrow has the capacity to make cells. It is simply not receiving the signal. This is EPO deficiency anemia, not iron deficiency anemia. The distinction determines what treatment should logically address — and it is almost never explained to patients.
Iron infusions given without full iron assessment
Standard practice uses ferritin as the primary iron marker. The problem: ferritin is an acute phase reactant. Dialysis patients have chronic systemic inflammation — their ferritin is chronically elevated regardless of actual iron stores. This means ferritin can read "adequate" while actual iron availability at the cellular level is deficient, or alternatively while iron is accumulating dangerously in tissues.
Full iron assessment requires: serum iron, TIBC (total iron-binding capacity), transferrin saturation (TSAT), and ferritin interpreted in the context of inflammatory markers such as CRP.
Iron overload from repeated IV iron infusions causes hemosiderin deposits in the liver, heart, and joints; increased oxidative stress; and cardiovascular damage. This is not a rare or theoretical risk in patients receiving iron infusions across years of dialysis.
Erythropoiesis-Stimulating Agents (ESAs)
Epogen (epoetin alfa) · Aranesp (darbepoetin) · Mircera (methoxy PEG-epoetin)
Synthetic EPO given by injection to stimulate red blood cell production
FDA Black Box Warning
ESAs increase the risk of death, serious cardiovascular events including heart attack, stroke, and venous thromboembolism, and tumor progression in patients with cancer. Risk is increased when hemoglobin targets are higher. The dose should be reduced or interrupted when hemoglobin approaches 11 g/dL.
TREAT Trial, 2009 — New England Journal of Medicine
Darbepoetin targeting hemoglobin of 13 g/dL increased stroke risk by 50% versus placebo in CKD patients not yet on dialysis. This was not a marginal signal.
What patients are told
"This treats your anemia."
What the Black Box says
Reduce or interrupt when hemoglobin approaches 11 g/dL. Higher targets increase death and cardiovascular event risk.
Common side effects: worsening hypertension, blood clots, headaches, joint pain, flu-like symptoms, injection site reactions.
IV Iron Infusions
Venofer · Ferrlecit · Feraheme · Injectafer
Given to ensure iron availability for ESA-stimulated red blood cell production
What patients are told
"Your iron is low."
What isn't said
IV iron bypasses the body's normal iron regulation entirely. The gut mucosa normally controls iron absorption; IV administration dumps iron directly into the bloodstream, where it can accumulate in organs over years.
Injectafer (ferric carboxymaltose) — FDA Warning, 2020
Severe hypophosphatemia — a paradoxical phosphate drop — can cause serious muscle weakness, bone pain, and in extreme cases, respiratory failure. This FDA warning was added in 2020.
Feraheme (ferumoxytol): Iron nanoparticles used in dialysis patients; carries anaphylaxis risk; also used as MRI contrast in some clinical settings.
Activated Vitamin D Analogs
Calcitriol (Rocaltrol) · Paricalcitol (Zemplar) · Doxercalciferol (Hectorol)
Given when kidneys can no longer activate vitamin D, causing secondary hyperparathyroidism
The mechanism: Healthy kidneys convert stored vitamin D (25-OH D3) into its active hormonal form (1,25-OH D, calcitriol). In CKD, this conversion is impaired. The result: parathyroid hormone (PTH) rises uncontrolled — secondary hyperparathyroidism — pulling calcium from bones. Activated vitamin D analogs are prescribed to suppress this PTH rise.
What patients are told
"Your vitamin D is low. This will help your bones."
What needs to be in the conversation
This is a prescription activated hormone analog — not a supplement. The risks are specific and significant.
- Hypercalcemia risk: Elevated blood calcium from these medications accelerates vascular calcification — an already serious problem in dialysis patients — causing arterial stiffening and cardiovascular events.
- Adynamic bone disease: Excessive suppression of the parathyroid glands with activated D analogs can cause adynamic bone disease, where bone stops remodeling entirely. Paradoxically, the treatment intended to protect bones can make bones fragile in a different way.
- Cholecalciferol (D3 supplements) are not a safe alternative assumption in CKD: The conversion pathway that is broken in CKD can still produce hypercalcemia in some patients. Do not assume over-the-counter D3 supplements are safe without specific nephrology guidance.
Phosphate Binders
Sevelamer (Renvela) · Calcium Carbonate (PhosLo) · Lanthanum Carbonate (Fosrenol)
Dialysis removes phosphate — but not efficiently enough. Phosphate builds up and combines with calcium to calcify soft tissues and blood vessels.
Sevelamer: GI side effects including constipation, nausea, and bloating are common. It also causes metabolic acidosis and binds fat-soluble vitamins A, D, E, and K, reducing their absorption — creating additional nutrient depletion in patients already at risk.
Calcium carbonate-based binders (PhosLo): Deliver a significant calcium load with every dose. This calcium contributes directly to the vascular calcification already being driven by elevated phosphate — meaning the binder that treats one problem can worsen another. Calcium-based binders are increasingly avoided in dialysis for this reason.
Lanthanum carbonate (Fosrenol): Lanthanum is a rare earth element in the heavy metal class. Studies have documented lanthanum deposition in liver tissue, bone, and gastrointestinal tissue in long-term users. The long-term consequences of tissue deposition remain understudied. This information is not routinely communicated to patients before prescribing.
Heparin — Given at Every Session
Approximately 156 heparin administrations per year
Heparin is administered at every dialysis session to prevent clotting in the dialysis circuit. A patient on dialysis three times per week receives heparin approximately 156 times per year — every year they are on dialysis.
Risks: Bleeding complications; heparin-induced thrombocytopenia (HIT) — a paradoxical clotting disorder in which heparin causes dangerous clotting rather than preventing it; and cumulative anticoagulation effects between sessions. Patients on warfarin or other anticoagulants face compounded bleeding risk that requires careful management.
Cinacalcet (Sensipar)
Used for secondary hyperparathyroidism
Cinacalcet works by mimicking calcium at the parathyroid gland receptor, reducing PTH secretion. It is an alternative or addition to activated vitamin D analogs for controlling secondary hyperparathyroidism.
Side effects patients should know about:
- Hypocalcemia: Low calcium that can trigger muscle spasms, tetany, seizures, QT interval prolongation, and cardiac arrhythmia.
- GI effects: Severe nausea and vomiting are among the most common reasons patients discontinue this medication.
- Adynamic bone disease: Excessive PTH suppression from cinacalcet, especially in combination with activated vitamin D analogs, can eliminate the normal bone remodeling signal.
Anticoagulation in Dialysis — Warfarin & the Calcification Risk
Warfarin (Coumadin) · the Matrix Gla Protein connection
Prescribed for atrial fibrillation, mechanical heart valves, and clotting risk — extremely common in the dialysis population
Warfarin is one of the most widely prescribed drugs in dialysis. Atrial fibrillation is common in the setting of uremia-related cardiac remodeling, and hypercoagulable states are also more prevalent. The anticoagulation rationale is sound. What is almost never disclosed is what warfarin does to the vascular walls of someone who is already accumulating calcium-phosphate deposits.
What those on dialysis are told
"Your blood is clotting too easily. This thins your blood and reduces stroke and clot risk."
What isn't in that conversation
Warfarin blocks vitamin K-dependent activation of Matrix Gla Protein — the primary protein that prevents calcium from depositing in vessel walls. In a dialysis patient already prone to vascular calcification, warfarin removes the body's main anti-calcification defense.
The Matrix Gla Protein (MGP) mechanism
Matrix Gla Protein is produced in the smooth muscle cells lining blood vessel walls. Its job is to bind calcium ions and prevent them from nucleating into crystals in the vessel wall. To do this, MGP must undergo carboxylation — a vitamin K-dependent step. Warfarin blocks this step. Inactive, non-carboxylated MGP (ucMGP) accumulates in vessel walls but cannot bind calcium. The result: free calcium deposits without inhibition.
Multiple studies document: (1) significantly elevated ucMGP levels in dialysis patients on warfarin; (2) elevated ucMGP strongly predicting vascular calcification progression; (3) significantly higher calciphylaxis rates in warfarin-treated dialysis patients compared to those on non-warfarin anticoagulation. This is not speculative. It is a mechanistically established and clinically documented pathway. The conversation about whether warfarin is the right anticoagulant for someone already on calcium-based phosphate binders and activated vitamin D analogs has clinical urgency — and it is rarely initiated by the prescribing physician.
Alternative anticoagulants and their considerations: Direct oral anticoagulants (DOACs — apixaban, rivaroxaban, dabigatran) do not block the vitamin K-dependent carboxylation pathway and therefore do not have the MGP-mediated calcification effect. Their use in dialysis patients is not straightforward — most DOACs are renally cleared, and dosing in ESRD requires specific guidance. Apixaban has the most accumulated data for use in dialysis and is used at reduced dosing in some centers. The discussion about whether a specific anticoagulation indication in a dialysis patient warrants warfarin versus a DOAC specifically because of calcification risk is one that should happen — and almost never does.
If already on warfarin: Tight INR control reduces the time spent at supra-therapeutic levels that maximize vitamin K antagonism. Adequate dietary vitamin K intake (within the INR management framework) may partially protect MGP activity. These are management conversations — not reasons to stop anticoagulation without clinical guidance — but they belong in the picture.
Vascular Access & The HeRO Graft
Vascular access is how blood reaches the dialysis machine and returns to the body. It requires surgery, it has a predictable failure rate, and each intervention changes what options are available next. This is information that belongs at the beginning of the access conversation.
The Access Hierarchy
What happens when each level fails
Arteriovenous Fistula (AVF)
Surgically created connection between artery and vein in the arm. Best long-term option — lowest infection and clotting rates.
What to know: Maturation failure occurs in 30 to 50% of patients. Can take 3 to 6 months to mature before use. Arm swelling and steal syndrome (arm ischemia from blood diversion) are possible complications.
Arteriovenous Graft (AVG)
Synthetic tube connecting artery to vein. Can be used sooner than a fistula — typically within 2 to 6 weeks of placement.
What to know: Higher infection and thrombosis rates than AVF. Typically requires reinterventions every 1 to 2 years to maintain function.
Tunneled Dialysis Catheter (TDC)
Catheter inserted through the neck into the heart. Immediate use — no maturation time required.
What to know: Highest infection rate of all access types. Central line-associated bloodstream infections (CLABSI) occur at 1 to 3 per 1,000 catheter days. Sepsis from catheter infection is a leading cause of death in dialysis patients. Each catheter also causes vein damage that reduces future access options.
HeRO Graft (last resort)
Used when central venous stenosis or occlusion has made all other upper extremity access impossible.
What to know: Permanent materials implanted in the body, MRI restrictions, significant reintervention rate. Full details below.
A cycle patients are not informed about
Central Venous Stenosis: The Catheter-Caused Problem
16 to 50% of long-term dialysis patients develop central venous stenosis or occlusion — narrowing or blockage of the large veins in the chest (subclavian, innominate, or superior vena cava). This damage is largely caused by prior dialysis catheters.
Each catheter insertion increases the risk of venous damage that will close off future access options in that arm. The catheter a patient needs now — because a fistula failed or maturation took too long — increases the probability that future access will be impossible on that side, eventually forcing the patient toward a HeRO graft. This progression is predictable, and it is rarely explained at the time of catheter placement.
HeRO Graft: Full Informed Consent
What it is and what it does
The HeRO (Hemodialysis Reliable Outflow) Graft is a hybrid device combining a surgically implanted arteriovenous graft in the arm (made of ePTFE) connected to a long silicone catheter — the Venous Outflow Component — that passes through the central veins and terminates in the right atrium of the heart, bypassing any venous occlusions in the chest.
What is permanently implanted in your body
From manufacturer documentation. These materials remain in the body for the life of the device.
Device lifetime: The ePTFE arterial graft is expected to last approximately 2 years before replacement. The silicone venous catheter component and adapter are designed for 10 years in-situ. Replacement of the arterial graft component requires surgery. The 45 grams of silicone catheter and titanium/nitinol hardware, however, remain in the body long-term.
What each material does biologically
These materials are classified as biocompatible — meaning they are not acutely toxic and have been approved for implantation. Biocompatible does not mean biologically inert over years in a patient with impaired kidney function, systemic inflammation, and poor detoxification capacity. The questions below are ones patients are entitled to ask.
Silicone — 45 g in the central veins and right atrium
Medical-grade silicone is the dominant material by volume in the HeRO device. A foreign body of this size in the cardiovascular system triggers a persistent chronic inflammatory response — the body's immune system continuously recognizes the catheter as non-self and mounts an ongoing reaction against it. This chronic inflammation elevates systemic inflammatory markers (CRP, IL-6, TNF-alpha) that are already elevated in dialysis patients. Systemic inflammation is an independent driver of vascular calcification — the same process underlying calciphylaxis and accelerated cardiovascular disease. The connection between silicone implants and systemic inflammatory conditions is an area of active study.
Nitinol (nickel-titanium alloy) — 5.55 g · approximately 55% nickel by weight
Nitinol implants release nickel ions over time through normal corrosion in the body's fluid environment. Studies have documented elevated serum nickel in patients with nitinol stents and devices. Nickel is classified as a Group 1 human carcinogen by IARC and is one of the most common metal allergens — estimated to affect 15–20% of the population, with higher rates in women. Nickel ions generate oxidative stress and inflammatory cytokines. In a patient whose kidneys cannot efficiently clear metal ions, circulating nickel may accumulate. Oxidative stress from metal ion release contributes to endothelial dysfunction — relevant to vascular calcification pathways. Patients should be evaluated for nickel sensitivity before nitinol implantation; this is rarely done.
Titanium alloy TiAl6V4 — 2.88 g · contains aluminum (6%) and vanadium (4%)
Titanium itself is well-tolerated. The alloy used — TiAl6V4 — contains aluminum and vanadium, which are more biologically active. Vanadium is a documented cellular toxin at elevated concentrations. Aluminum released from alloy corrosion is relevant in dialysis patients: aluminum historically caused dialysis encephalopathy, adynamic bone disease, and worsened anemia in patients who accumulated it from aluminum-containing phosphate binders. Although that source has largely been removed from clinical practice, additional aluminum from implant corrosion adds to total body burden in patients who cannot excrete it efficiently. Aluminum accumulation in bone is also linked to the paradoxical bone fragility seen in long-term dialysis patients.
ePTFE and FEP fluoropolymers — 4.57 g + 0.66 g · Teflon-family materials
ePTFE (expanded polytetrafluoroethylene) and FEP (fluorinated ethylene propylene) are members of the fluoropolymer family — the same chemical class as PFAS (per- and polyfluoroalkyl substances), which are documented nephrotoxins associated with GFR decline, kidney cancer, and immune dysregulation. As solid implants, these materials do not leach in the same way as soluble environmental PFAS. However, as the graft ages and begins to degrade, fluoropolymer microparticles and oligomers can be released into the bloodstream. The long-term behavior of ePTFE graft degradation products in a patient with impaired clearance is not a well-studied area — which is itself information patients deserve to have.
Barium sulfate, Platinum/Iridium, Silicone adhesive and ink
These are present in very small amounts and serve as radiopaque markers (making the device visible on X-ray). Barium sulfate in solid implanted form is considered biologically inert. Platinum/iridium is used in numerous medical implants and is well-tolerated. Silicone adhesives and device inks are the least characterized components — the exact composition of medical device inks is not always fully disclosed in public documentation, and some older formulations contained heavy metal pigments. The regulatory burden for disclosure of device ink composition is lower than for other implant materials.
Do these materials contribute to calciphylaxis, kidney decline, or muscle damage?
Calciphylaxis: The direct clinical link between HeRO graft materials and calciphylaxis has not been established in the literature. The indirect pathway is through chronic inflammation. Calciphylaxis is driven by vascular inflammation, oxidative stress, and calcium-phosphate dysregulation. All three are already severe in dialysis patients — and a 45-gram silicone catheter in the right atrium generating continuous foreign-body inflammatory signaling adds to that inflammatory burden. How much it contributes is not quantified. That it contributes nothing is also not established.
Kidney decline: In patients with residual kidney function, the hemodynamic changes from an AV graft (increased cardiac output, altered venous return) affect renal perfusion. Nickel and aluminum ion release from nitinol and titanium alloy are renally cleared — in patients with compromised clearance, these metals may accumulate. Systemic inflammation from the foreign body reaction elevates inflammatory mediators that accelerate residual kidney function loss. These are plausible mechanisms, not established causation.
Muscle: The steal syndrome mechanism — diversion of blood from the arm — causes tissue ischemia that affects muscle as well as skin. Chronic arm ischemia from the graft produces arm claudication (pain with use), weakness, and over time, muscle atrophy in the affected arm. This is a mechanical consequence of the graft's hemodynamic effect, not of the materials themselves.
MRI Restrictions — Not MRI Safe
The HeRO Graft is classified as MR Conditional — not MR Safe. This is a critical distinction that affects future medical care.
MR Conditional means:
- ⋅ Only 1.5 Tesla and 3.0 Tesla field strengths are approved
- ⋅ Specific spatial gradient magnetic field limits apply (40 T/m or less)
- ⋅ Specific SAR (specific absorption rate) limits apply (2 W/kg or less)
- ⋅ If conditions are not met at a given facility, MRI cannot safely proceed
Patients with a HeRO graft may be denied MRI access at certain facilities or require specialist clearance for every scan. If a neurological condition, cancer evaluation, or joint disease develops after HeRO placement — conditions routinely evaluated by MRI — access to that diagnostic tool becomes restricted or complicated.
Duke University 10-Year Study — n=232 patients
What the patency data actually shows
Primary Patency
Working without any additional procedure
Secondary Patency
Maintained with reinterventions
What this means in plain terms: 96% of HeRO grafts require repeated surgical or endovascular interventions just to remain functional by 3 years. The expected reintervention rate is 1.6 to 2.3 procedures per patient per year.
Complications — Duke 10-Year Data
Patients are entitled to know these numbers
For context: a perioperative MI rate above 1% is considered high for any non-cardiac procedure. A pulmonary embolism rate above 1% is high for most surgeries. Nearly 1 in 10 patients experiencing arm ischemia — and nearly 1 in 18 having the graft removed within 90 days due to infection — are significant numbers in any population. In patients who are already cardiovascular-compromised, immunologically impaired, and have poor wound healing, these risks carry additional weight.
Steal syndrome — arm ischemia
Ischemia means the tissue is being starved of oxygen. The HeRO graft works by routing blood from the arm artery into the dialysis circuit. In steal syndrome, the graft diverts so much blood away from the hand and lower arm that those tissues stop getting adequate circulation. The hand becomes cold, painful, numb, and weak. If uncorrected it can progress to open wounds that won't heal, tissue death (gangrene), and amputation. Correcting it typically requires an additional surgical procedure — or graft removal.
Symptomatic hematoma requiring intervention
A hematoma is blood that leaks out of a vessel and pools in the surrounding tissue — a deep bruise, but larger and under pressure. When blood pools around a newly placed graft, it can compress the graft itself, compress arm nerves, and cause significant pain and swelling. When it doesn't resolve on its own, it requires a procedure to drain it. "Requiring intervention" means it passed the threshold where watchful waiting was no longer sufficient.
Wound infection
Dialysis patients have impaired immune function and poor wound healing — a combination that makes any surgical site infection more serious than it would be in a healthy person. The graft itself is a synthetic foreign object, and once a foreign body becomes infected, the infection is often impossible to fully clear with antibiotics alone. Many surgical wound infections in this population become graft infections — requiring the entire device to be removed.
Pulmonary embolism
A blood clot that travels to the lungs, blocking blood flow through the pulmonary artery. The HeRO catheter terminates inside the right atrium of the heart — the chamber that pumps blood directly to the lungs — and its presence can contribute to clot formation in the central venous system. A pulmonary embolism in a dialysis patient, who already has a cardiovascular system under significant chronic stress, carries higher mortality risk than in the general population. The general surgical PE rate is typically below 1%. This figure is 3%.
Infection requiring graft removal — within 90 days
Nearly 1 in 18 patients needed the entire HeRO graft surgically removed within the first 90 days because of uncontrollable infection. This means the procedure failed — catastrophically — before it had been in place long enough to prove its value. The patient then returns to temporary catheter access while the site heals, often with a compromised venous anatomy from the attempt. The 90-day window is significant: it is the period before the graft has been tested under real clinical conditions for any meaningful duration.
Myocardial infarction — perioperative
A heart attack occurring during or immediately after surgery. 1.3% is considered high for any non-cardiac procedure. In a population where cardiovascular disease already kills 10 to 30 times more patients than the general population, a perioperative heart attack is not a minor complication — it is a potentially fatal event in a body that was already under severe cardiac strain before the graft was placed.
Additional Restrictions Not Routinely Communicated
Permanent limitations after HeRO placement
No central line or medical device placement on the same side as the HeRO graft — ever. No standard venous access on the ipsilateral side. Any intervention in the device area requires advance review of device specifications. The manufacturer documentation states: "DO NOT attempt intervention without device information."
Tapered conduit — what you should ask before surgery
The HeRO graft includes a tube — called the conduit — that carries blood from the arm graft into the venous catheter. This tube comes in different diameters. Some are uniform-width throughout. Others are tapered — wider at one end and narrower at the other (narrowing from 6 mm down to 4 mm, or from 7 mm down to 4 mm).
In plain terms: a narrower tube carries less blood flow and creates more turbulence at the narrowing point. Turbulence at a junction inside a blood vessel promotes clot formation and accelerates wear on the graft lining — both of which contribute to graft failure.
The Duke 10-year analysis found that tapered conduits were associated with 2 to 3 times higher rates of early graft failure — meaning a graft placed with a tapered tube is two to three times more likely to stop working and require a repair procedure, compared to a graft placed with a uniform-diameter conduit. This finding comes from multivariate analysis, meaning it held up even when accounting for other differences between patients.
Despite this, tapered conduits are still routinely used. The choice of conduit size is a surgical variable — it is a decision the surgeon makes, and it affects how long the graft is likely to function without additional intervention. Patients are rarely told conduit size matters. The question to ask before surgery: "What diameter conduit are you planning to use, and is there a clinical reason to use a tapered rather than a uniform-diameter conduit for my anatomy?"
What to Ask
These questions are not adversarial. They are the questions that complete the informed consent process. Every person facing dialysis is entitled to answers to all of them.
Before consenting to dialysis
The conversation that should happen first
"What is my estimated survival on dialysis versus conservative kidney management, given my age and specific comorbidities?"
Not a general statistic — your specific profile: heart disease, diabetes, functional status, mobility. These change the calculus significantly.
"How much of that additional time with dialysis would I spend in a medical facility versus at home?"
The research shows this question has a meaningful answer. The time difference in median survival may be smaller than the difference in time spent in versus out of care settings.
"What does conservative kidney management include, and who provides it?"
You are entitled to this option explained as clearly as dialysis is explained. If it is dismissed without detail, ask again.
"Am I a transplant candidate? What is the realistic wait time at this center?"
If transplant is not realistic for your specific situation, the calculus for years of dialysis changes significantly.
"What does a typical week look like on dialysis for someone with my current health and functional status?"
Not a general description. Specific to you — your commute, your current fatigue, your employment, your family situation.
Before starting ESAs (EPO injections)
Epogen, Aranesp, Mircera
"What hemoglobin target are you aiming for, and how does that compare to the evidence-based caution level of 11 g/dL?"
The FDA Black Box Warning is specific on this. Higher targets increase cardiovascular event and death risk.
"How will you monitor me for cardiovascular events and blood clots while I am on this medication?"
ESAs carry a Black Box Warning for these events. Monitoring protocol should be explicit, not assumed.
"Will you assess my stroke risk specifically before starting?"
The TREAT trial found a 50% increase in stroke risk. Prior stroke history or risk factors are relevant to this prescription.
Before iron infusions
Venofer, Ferrlecit, Feraheme, Injectafer
"Can you show me the full iron panel — serum iron, TIBC, transferrin saturation, and ferritin?"
Ferritin alone is not sufficient in dialysis patients. The full panel tells a different story.
"Is my elevated ferritin reflecting actual iron stores, or is it elevated because of inflammation?"
Ferritin is an acute phase reactant. In dialysis patients with chronic systemic inflammation, it is often not an accurate iron marker.
"What is my CRP or other inflammation marker, and how does that affect how you are interpreting my ferritin?"
If CRP is elevated, ferritin is unreliable as a standalone iron assessment.
"Are you monitoring for iron accumulation in my tissues over time, given how many infusions I have had?"
Iron overload from repeated IV infusions causes hemosiderin deposits in organs. This is a cumulative risk.
Before vascular access surgery
Especially before HeRO graft placement
"Are there any remaining upper extremity options that have not been exhausted before proceeding to a HeRO graft?"
HeRO is a last-resort device. The threshold for that determination should be explicit.
"What is the expected primary patency at 1, 3, and 5 years for this device?"
The Duke data shows 33% at 1 year and 6.4% at 3 years. You deserve these numbers before signing consent.
"How many reinterventions per year should I expect to maintain this access?"
1.6 to 2.3 procedures per year is the documented rate. This means additional surgeries, anesthesia, and recovery on a near-annual basis.
"What are my MRI restrictions after this device is implanted?"
The HeRO is MR Conditional — not MR Safe. You need to know this before you need an MRI for another condition.
"What materials are permanently in my body, and what is the expected lifetime of each component?"
You are entitled to know what is being implanted — including nitinol, titanium alloy, ePTFE, silicone, and barium sulfate — before you consent.
"Will you be using a tapered conduit, and if so, how does that affect my patency outcomes?"
Tapered conduits are associated with 2 to 3 times higher loss of primary patency. Conduit choice affects outcomes.
Before prescription activated vitamin D
Calcitriol, paricalcitol, doxercalciferol
"Is this a prescription activated vitamin D analog, or a cholecalciferol supplement? What is the distinction?"
These are fundamentally different. Activated analogs bypass the kidneys and act directly on receptors — and carry risks that cholecalciferol does not in the same way.
"Will you monitor my calcium levels and vascular calcification markers while I am on this?"
Hypercalcemia from activated D analogs accelerates vascular calcification, which is already a major risk in dialysis patients.
"What is my current parathyroid hormone level, what is the target, and how will you avoid over-suppressing it?"
Excessive PTH suppression leads to adynamic bone disease — a different bone problem than the one the medication is treating.
A note on asking
These questions belong in the room before you sign
A physician who is unwilling to answer these questions has not completed the informed consent process. Informed consent is not a signature on a form — it is the result of a complete conversation. You are entitled to take time, bring someone with you, ask for written materials, and request a second opinion.
This page is educational and does not constitute medical advice. It is intended to help you participate fully in your own care decisions.
What Damages Kidneys
Before the conversation turns to dialysis, there is another conversation that is almost never had: what has been damaging the kidneys, how long has it been going on, and how much of it is reversible. In clinical practice, removing the inputs changes the trajectory — sometimes dramatically.
Clinical observation
eGFR 18 to 52 in approximately three months
When two variables are addressed — ferritin is brought down to a non-inflammatory range and vitamin D supplementation is stopped — kidney function in some patients improves substantially. An eGFR of 18 (ESRD threshold) returning to 52 (moderate CKD) in roughly three months represents a trajectory that completely changes the clinical conversation. This does not happen in every patient, and it does not happen without identifying and removing what has been causing the damage. But it happens often enough that the conversation about what is driving kidney deterioration belongs before any conversation about dialysis.
The two most commonly overlooked reversible inputs: vitamin D supplement burden (slow soft tissue and tubular calcification) and iron overload (direct oxidative toxicity to renal tubular cells, chronic inflammatory signaling). Both accumulate silently. Both respond to removal.
Vitamin D Supplements
Tubular calcification — slow, silent, and not regularly checked
The kidneys are the primary organ responsible for converting stored vitamin D (25-OH D3) into its active form and for excreting excess calcium. When D3 supplements are taken long-term, particularly at higher doses, calcium levels rise — sometimes subtly, within lab "normal" ranges — and calcium deposits in renal tubular cells accumulate over months and years. This is nephrocalcinosis. It impairs filtration directly.
Vitamin D supplements accumulate in adipose tissue and do not clear quickly — the body stores them for months. Lab values may normalize while tissue burden continues. Stopping supplementation is the first step; recovery of tubular function often follows over a period of weeks to months.
- Hypercalcemia from D3 supplementation does not require "toxicity" doses — it can occur at 2,000–4,000 IU/day in susceptible individuals, particularly over years.
- Calcium oxalate kidney stones are more likely when calcium is chronically elevated from supplementation.
- The kidneys cannot excrete what they cannot process — in CKD, the conversion and excretion capacity is already impaired, making supplement burden more consequential, not less.
- The correct alternative: sunlight drives endogenous D3 production with built-in regulatory feedback. The skin stops producing when enough has been made. Supplements have no such feedback.
Iron Overload & Ferritin
Direct nephrotoxicity — the Fenton reaction in renal tubular cells
Excess iron generates hydroxyl radicals through the Fenton reaction — one of the most reactive oxidizing species known. Renal tubular cells are particularly vulnerable. When serum iron is chronically elevated or when repeated IV iron infusions deposit iron in tissues over years, direct oxidative damage to the nephron occurs. This is not a theoretical concern. It is the mechanism by which hemochromatosis destroys kidneys, and it operates at lower levels of iron excess as well.
Ferritin is an acute phase reactant. Elevated ferritin in the presence of chronic inflammation (universal in CKD, common in many undiagnosed conditions) does not confirm iron excess — but it does confirm inflammation. That inflammation is its own driver of renal damage. Getting ferritin to a non-inflammatory range addresses both the iron burden and the inflammatory signaling that sustains tubular injury.
Full iron assessment before any iron infusion:
Serum iron + TIBC + transferrin saturation (TSAT) + ferritin interpreted alongside CRP. Ferritin alone will overestimate iron deficiency in anyone with chronic inflammation — and under-diagnose iron overload in anyone whose ferritin is being elevated by the inflammatory signal rather than by iron stores.
Contrast Agents
Iodinated contrast (CT scans, angiograms) and gadolinium (MRI)
Contrast-induced acute kidney injury (CI-AKI) occurs when iodinated contrast causes renal vasoconstriction and direct tubular toxicity. eGFR is frequently not checked before routine CT scans ordered in outpatient and ER settings. In a patient with already-reduced kidney function, a single contrast CT can drop eGFR by 20–30% — sometimes enough to cross from CKD stage 3 into stage 4, or stage 4 into stage 5.
Risk is compounded when the patient is also taking NSAIDs, diuretics, or ACE inhibitors — all of which reduce the renal blood flow the kidney needs to handle contrast. Dehydration at time of scan is an independent amplifier. None of these are consistently checked before contrast administration.
Gadolinium (MRI contrast): In patients with eGFR below 30, gadolinium can cause nephrogenic systemic fibrosis (NSF) — a severe, potentially fatal condition causing fibrosis of skin, joints, and internal organs. Linear gadolinium agents have been withdrawn from the EU for systemic use. Gadolinium retention in brain tissue has been documented even in patients with normal kidney function, at any dose.
The consent gap: Those with kidney disease are rarely told that the CT scan ordered to evaluate their abdomen, chest, or brain could measurably reduce their kidney function — or that their current medications make that risk higher.
What contrast can do to the heart — the NT-proBNP story
NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a cardiac stress marker. The heart releases it when ventricular walls are under pressure — from fluid overload, from reduced cardiac output, or from acute cardiac injury. In a healthy person, NT-proBNP is typically below 125 pg/mL. In dialysis patients, elevated baseline values are common because cardiac stress is already chronic.
What is not disclosed before contrast procedures in cardiac-compromised kidney patients is how catastrophically NT-proBNP can rise in the acute period following contrast exposure. The sequence is well documented but almost never presented to the person being asked to consent to an angiogram or contrast CT:
Step 1 — Contrast causes acute tubular injury
Iodinated contrast is directly toxic to the tubular epithelium and causes renal vasoconstriction. In a patient whose kidneys are already functioning at reduced capacity, this acute insult drops filtration further — sometimes precipitously. In dialysis patients, residual kidney function is already minimal or absent; the contrast injury eliminates whatever remained and forces the entire fluid and waste management burden onto the dialysis schedule.
Step 2 — Fluid accumulates faster between sessions
Contrast media is osmotically active — it pulls fluid into the vascular space, temporarily increasing circulating volume. In a person who cannot urinate and is waiting for their next dialysis session, this fluid cannot be cleared. Pulmonary edema, peripheral edema, and rising blood pressure can develop rapidly. The heart, already working against a calcified and stiffened vascular system, begins to fail acutely under the volume load.
Step 3 — NT-proBNP tracks the cardiac response in real time
NT-proBNP is the marker that shows this happening. A value that starts at 300 pg/mL — already reflecting baseline cardiac stress — can reach 45,000 pg/mL in the days following a contrast-heavy cardiac procedure. That is a 150-fold increase in cardiac stress marker in a matter of days. The heart is not failing slowly. It is decompensating acutely. This is not an unusual or exceptional outcome in this population — it is a predictable consequence of giving contrast to someone whose kidneys cannot clear it and whose heart cannot absorb the resulting fluid and hemodynamic insult.
What the consent form says: "Risk of kidney injury." What the consent form does not say: your NT-proBNP may go from 300 to 45,000. Your heart may decompensate acutely in the days after this procedure. You may need urgent or emergent dialysis. You may not recover to your pre-procedure cardiac baseline.
NT-proBNP is almost never tracked before and after contrast procedures in dialysis patients. It is tracked in acute heart failure admissions, in transplant evaluations, and in cardiology follow-up — but not as a pre- and post-procedure monitoring tool for contrast-induced cardiac decompensation in the kidney disease population. The number that would tell the story is not being measured. The story is not being told.
The question to ask before any contrast procedure: "What is my current NT-proBNP, what was it at my last baseline, and what monitoring is planned for cardiac status in the 48 to 72 hours after this procedure?" If there is no monitoring plan — that is the consent gap.
Pharmaceutical Drugs That Damage Kidneys
Nephrotoxicity is one of the most common causes of preventable kidney disease
Drug-induced kidney injury accounts for 20% of community-acquired acute kidney injury and up to 30% of hospital-acquired cases. Most of the drugs listed below are still routinely prescribed to patients who already have compromised kidney function — often without disclosure of that risk, and often without monitoring. The given in CKD tag marks drugs commonly prescribed to kidney patients.
The "Triple Whammy" — Triples AKI Risk
NSAID + ACE inhibitor or ARB + diuretic — taken together, this combination is one of the most common causes of acute kidney injury in outpatient medicine. NSAIDs block prostaglandin-mediated renal vasodilation. ACE inhibitors/ARBs reduce efferent arteriolar resistance. Diuretics reduce circulating volume. Together they collapse renal perfusion pressure. This combination is prescribed routinely to elderly hypertensive patients. Patients are almost never told that taking their arthritis medication with their blood pressure drugs creates a documented kidney emergency risk.
NSAIDs — Prostaglandin-Mediated Renal Vasoconstriction
Ibuprofen (Advil, Motrin)
Blocks afferent arteriolar dilation; acute AKI within days in at-risk patients; OTC availability means patients don't report use.
Naproxen (Aleve, Naprosyn)
Same mechanism; longer half-life means sustained prostaglandin suppression; OTC.
Diclofenac (Voltaren, Cataflam)
Same mechanism; topical gel form is not zero-risk — still absorbs systemically.
Celecoxib (Celebrex)
COX-2 selective — still suppresses prostaglandin-mediated renal protection; marketed as kidney-safer but evidence does not support that framing in CKD.
Meloxicam (Mobic)
Widely substituted for ibuprofen in CKD patients as "safer" — it is not; same renal mechanism, same AKI risk.
Indomethacin (Indocin)
One of the most potent prostaglandin inhibitors; used in gout and premature labor; significant renal vasoconstriction.
Ketorolac (Toradol)
IV/IM NSAID given in emergency settings; among the most nephrotoxic NSAIDs; contraindicated in CKD but administered in ERs routinely without checking kidney function.
Aspirin — high dose (Bayer, Ecotrin)
Low-dose aspirin (81mg) has minimal renal effect; high-dose analgesic use causes papillary necrosis with long-term use (analgesic nephropathy).
PPIs — Proton Pump Inhibitors
Linked to AIN and accelerated CKD progression. 2016 JAMA Internal Medicine: 28% higher CKD risk, 96% higher ESRD risk vs. H2 blockers. Not approved for long-term use; routinely prescribed for years — including in dialysis patients.
Omeprazole (Prilosec, Losec)
AIN; CKD progression; OTC availability normalizes long-term use.
Pantoprazole (Protonix)
Most common IV PPI in hospitals; given to virtually every admitted patient "for stress ulcer prophylaxis" regardless of kidney status.
Lansoprazole (Prevacid)
AIN; CKD progression; same class risk.
Esomeprazole (Nexium)
AIN; CKD progression; heavy direct-to-consumer marketing normalized long-term use.
Rabeprazole (Aciphex)
Same class risk.
Dexlansoprazole (Dexilant)
Dual-release formulation; same class risk; no renal safety advantage demonstrated.
ACE Inhibitors & ARBs — Efferent Arteriolar Dilation
Prescribed to slow CKD progression — and they do reduce proteinuria. However, they also reduce GFR by relaxing the efferent arteriole. Creatinine typically rises 10–20% when started, which is expected. In the triple-whammy combination (with NSAIDs + diuretics) they precipitate acute kidney failure. Bilateral renal artery stenosis is an absolute contraindication — rarely checked before prescribing.
Lisinopril (Prinivil, Zestril)
Most prescribed ACE inhibitor; standard CKD/hypertension treatment; triple-whammy risk when combined with NSAID + diuretic.
Enalapril (Vasotec)
Same mechanism; prodrug converted in liver to active form.
Ramipril (Altace)
Same; evidence-based in post-MI and diabetic nephropathy but triple-whammy risk remains.
Losartan (Cozaar)
ARB — same efferent arteriolar mechanism as ACE inhibitors without the cough side effect; standard CKD/diabetic nephropathy treatment.
Valsartan (Diovan)
ARB; same mechanism; triple-whammy risk applies.
Olmesartan (Benicar)
ARB; associated with sprue-like enteropathy at high doses (separate issue from renal); same efferent mechanism.
Diuretics — Volume Depletion & Electrolyte Depletion
Furosemide (Lasix)
Loop diuretic; volume depletion reduces renal perfusion; ototoxicity at high doses; almost universally prescribed to CKD/heart failure patients.
Bumetanide (Bumex)
Loop diuretic; 40x more potent than furosemide by weight; same mechanism and risks.
Torsemide (Demadex)
Loop diuretic; longer acting; same risks.
Hydrochlorothiazide (HCTZ, Microzide)
Thiazide; volume depletion; hypokalemia, hyponatremia, hypomagnesemia; loses effectiveness when eGFR drops below 30 but continues to deplete electrolytes.
Chlorthalidone (Hygroton, Tenoretic)
Longer-acting thiazide; more sustained electrolyte depletion.
Spironolactone (Aldactone)
Potassium-sparing; hyperkalemia risk becomes dangerous as eGFR declines; cardiac arrhythmia risk from potassium accumulation.
Triamterene (Dyrenium, in Maxzide)
Potassium-sparing; triamterene crystals can deposit directly in renal tubules, causing obstructive nephropathy.
The Standard Combination — What It Does to the Kidneys Over Time
Furosemide (Lasix) + Spironolactone — prescribed together for heart failure with cirrhosis
This combination is standard of care for fluid overload in patients with both heart failure and cirrhotic liver disease. It works — it removes fluid. What it does not do is fix the reason the fluid is accumulating. And over months and years, it creates a clinical trap that is rarely explained to the patient.
The paradox: fluid overloaded and volume depleted at the same time
In cirrhosis, the liver disease causes splanchnic vasodilation — blood pools in the gut's blood vessels, effectively pulling it out of active circulation. The body reads this as low blood volume and activates the RAAS (renin-angiotensin-aldosterone system) to retain sodium and water. The result: total body fluid rises (ascites, edema, weight gain) while the effective arterial blood volume — the fluid available to perfuse the kidneys and heart — is actually low. When furosemide is given into this situation, it removes fluid from circulation and the kidneys — the very compartment that was already underperfused. The ascites and edema may not budge, but the kidney blood flow drops further. Creatinine rises. The dose gets increased. The cycle repeats.
Diuretic resistance — why the dose keeps going up
Furosemide is 98% protein-bound in the bloodstream — it requires albumin to be carried to the kidney tubule where it works. In cirrhosis, albumin falls because the damaged liver can no longer make enough. Less albumin means furosemide can't reach its target efficiently — so the drug that looked like it was working at 40mg starts failing at 80mg or 120mg. Meanwhile, each dose triggers a RAAS counter-surge: the body activates renin and aldosterone to recapture the sodium that was just lost. Post-diuretic sodium rebound between doses undoes much of the effect. The prescription gets escalated. The kidneys get more underperfused with each escalation. This is called diuretic resistance, and it is an almost inevitable consequence of long-term furosemide in liver disease — yet patients are rarely told it is coming.
Spironolactone — the potassium and kidney risk as eGFR falls
Spironolactone blocks aldosterone, which causes the kidney to retain potassium instead of excreting it. In mild-to-moderate kidney disease, this can be managed. As eGFR falls below 30, potassium accumulates — and elevated serum potassium (hyperkalemia) causes cardiac arrhythmias and sudden death. A patient on spironolactone whose kidney function is declining faces an escalating hyperkalemia risk that may not be monitored closely enough. Standard monitoring recommends electrolytes every 1–3 months; patients with declining kidney function need more frequent checks. The drug that was helping their ascites becomes a cardiac risk as the kidneys deteriorate.
What the combination depletes — every dose, indefinitely
Loop diuretics deplete: potassium, magnesium, sodium, calcium, thiamine (B1), zinc. Magnesium depletion is the most clinically underrecognized — it causes muscle cramping, restless legs, cardiac arrhythmias, and worsens potassium depletion (you cannot correct low potassium until magnesium is replaced). Thiamine depletion from loop diuretics is documented and clinically significant — thiamine deficiency causes Wernicke's encephalopathy and wet beriberi (a form of cardiac failure). In a patient already taking furosemide for cardiac failure, thiamine depletion can directly worsen the heart condition being treated. None of this is routinely monitored or supplemented in standard practice.
The question that is not asked: What is causing the fluid to accumulate in the first place — and is any of it addressable? Fluoride burden in patients with impaired renal clearance, thyroid suppression producing diastolic dysfunction, low albumin from liver disease, medications that cause fluid retention (calcium channel blockers, NSAIDs, corticosteroids) — these are addressable inputs. The diuretic manages the symptom. It does not change the trajectory. And in the context of failing kidneys and a failing liver, the diuretic is simultaneously necessary and nephrotoxic. Patients are entitled to know this is the situation they are in.
Aminoglycosides — Direct Proximal Tubular Toxicity
Accumulate in the renal cortex; proximal tubular necrosis occurs in 10–25% of courses. Used in hospital settings, often in patients who already have reduced kidney function. Risk increases with dehydration, concurrent NSAIDs, and contrast exposure.
Gentamicin
Most commonly used aminoglycoside; proximal tubule accumulation with once-daily dosing being somewhat safer; requires trough monitoring.
Tobramycin
Used for Pseudomonas; similar nephrotoxicity profile to gentamicin.
Amikacin
Reserved for resistant infections; nephrotoxic; requires dose reduction in CKD (often not performed adequately).
Streptomycin
Tuberculosis treatment; nephrotoxic and ototoxic; still used in drug-resistant TB protocols.
Neomycin
Oral preparation for hepatic encephalopathy; normally minimally absorbed — but in compromised GI mucosa, absorption increases and tubular toxicity follows.
Glycopeptide Antibiotics — Tubular Toxicity
Vancomycin (Vancocin)
Direct tubular toxicity; risk dramatically increased in combination with NSAIDs, diuretics, or aminoglycosides — combinations common in hospitalized CKD patients. Requires therapeutic drug monitoring that is inconsistently performed.
Teicoplanin
European equivalent of vancomycin; similar nephrotoxicity profile.
Fluoroquinolone Antibiotics — AIN & Direct Tubular Injury
A 2013 BMJ study found a 2.4-fold increase in acute kidney injury within 14 days of fluoroquinolone dispensing. Widely prescribed for urinary tract infections — including in patients with existing CKD — without dose adjustment conversation or monitoring plan. Also implicated in acute interstitial nephritis and tendon/mitochondrial toxicity independent of the kidney effect.
Ciprofloxacin (Cipro)
Most prescribed fluoroquinolone for UTIs in CKD patients; AIN; direct tubular injury; crystalluria at high doses or poor hydration.
Levofloxacin (Levaquin)
Same class; requires dose reduction in CKD that is frequently omitted; longer half-life increases tubular exposure time.
Moxifloxacin (Avelox)
Respiratory fluoroquinolone; same AIN risk; hepatically eliminated — often substituted in CKD thinking renal dosing is not needed, but tubular toxicity still occurs.
Norfloxacin (Noroxin)
UTI-specific fluoroquinolone; same class risk; requires dose adjustment rarely performed.
Sulfonamides — AIN & Creatinine Masking
Trimethoprim-sulfamethoxazole (Bactrim, Septra)
Trimethoprim blocks tubular creatinine secretion — creatinine rises 0.1–0.4 mg/dL without any true change in GFR (misleadingly triggers CKD workups). Also causes true AIN and dangerous hyperkalemia in CKD by blocking potassium excretion. Extremely widely prescribed.
Antifungals — Tubular Toxicity & Electrolyte Wasting
Amphotericin B (Fungizone)
Most nephrotoxic antibiotic in common clinical use. Causes renal tubular acidosis (type 1), nephrogenic diabetes insipidus, and AKI in 30–80% of patients. Wasting of potassium and magnesium is severe and requires constant replacement. Used in severe fungal infections — often in already-compromised patients.
Amphotericin B liposomal (AmBisome)
Lipid formulation reduces but does not eliminate nephrotoxicity; still causes tubular damage and electrolyte wasting. Preferred over conventional AmB but not kidney-safe.
Fluconazole (Diflucan)
Generally better tolerated than amphotericin; accumulates in renal failure; dose reduction required at eGFR <50 — frequently omitted.
Antivirals — Proximal Tubular Toxicity & Crystalluria
Tenofovir disoproxil fumarate / TDF (Viread, Truvada, Atripla, Complera, Stribild)
Proximal tubular dysfunction; Fanconi syndrome (phosphate, glucose, amino acid wasting); progressive CKD develops in a subset of HIV patients on long-term TDF. eGFR decline is gradual and often missed until significant.
Tenofovir alafenamide / TAF (Descovy, Biktarvy, Genvoya)
Newer formulation with lower plasma levels; less nephrotoxic than TDF but not zero — proximal tubular effects still documented.
Cidofovir (Vistide)
CMV treatment; severe nephrotoxicity requiring probenecid pretreatment and IV hydration with every dose to prevent tubular destruction. Used only in patients for whom no alternative exists.
Adefovir (Hepsera)
Hepatitis B treatment; proximal tubular nephropathy at doses above 10mg/day; replaced largely by tenofovir but still used.
Acyclovir high-dose IV (Zovirax)
Acyclovir crystals precipitate in renal tubules at high IV doses without adequate hydration; obstructive nephropathy; requires IV saline prehydration that is sometimes skipped in busy inpatient settings.
Chemotherapy — Tubular Toxicity & Thrombotic Microangiopathy
Cisplatin (Platinol)
Most nephrotoxic chemotherapy agent in common use; direct proximal and distal tubular toxicity in 20–35% of patients; cumulative with each cycle; magnesium and potassium wasting severe and permanent in some patients.
Carboplatin
Less nephrotoxic than cisplatin but dose-limited by kidney function; thrombocytopenia + renal toxicity accumulate with cycles.
Methotrexate — high dose
Precipitates in renal tubules at acidic urine pH; requires urine alkalinization with sodium bicarbonate and leucovorin rescue; AKI common without strict protocol; urine pH often not checked.
Ifosfamide (Ifex)
Causes Fanconi syndrome (proximal tubular destruction) and hemorrhagic cystitis; renal tubular acidosis; phosphate wasting; particularly severe in children.
Gemcitabine (Gemzar)
Thrombotic microangiopathy (TMA) — clots in small renal vessels causing HUS-like syndrome; cumulative with long-term therapy.
Bevacizumab (Avastin)
Anti-VEGF; causes thrombotic microangiopathy, proteinuria, and hypertension; VEGF is required for glomerular endothelial cell survival — blocking it damages the filtration membrane.
Mitomycin C
TMA and hemolytic uremic syndrome (HUS) — severe and often irreversible; cumulative dose-related.
Immunosuppressants — Calcineurin Inhibitor Nephrotoxicity
Tacrolimus (Prograf, Envarsus, Astagraf)
Given to every kidney transplant patient to prevent rejection — the leading cause of late kidney transplant failure is tacrolimus-induced nephrotoxicity. Chronic vasoconstriction of the afferent arteriole; interstitial fibrosis develops silently over years. Patients are not told the drug protecting their transplant is also destroying it.
Cyclosporine (Sandimmune, Neoral, Gengraf)
Same calcineurin inhibitor mechanism as tacrolimus; chronic tubulointerstitial fibrosis; also used in autoimmune conditions (psoriasis, rheumatoid arthritis) where kidney monitoring is less rigorous.
Sirolimus / Rapamycin (Rapamune)
mTOR inhibitor used post-transplant; causes proteinuria and worsens CKD in some patients despite not having calcineurin inhibitor mechanism; tubular toxicity and impaired tubular repair.
Everolimus (Afinitor, Zortress)
mTOR inhibitor; same proteinuria and CKD progression risk as sirolimus.
Psychiatric Medications — Tubular Injury & Rhabdomyolysis
Lithium (Lithobid, Eskalith)
Nephrogenic diabetes insipidus and chronic tubulointerstitial nephritis; up to 20% of patients on lithium 10+ years develop CKD; damage is often irreversible by detection. eGFR is supposed to be monitored every 6 months — in practice this frequently does not happen.
Quetiapine (Seroquel)
Rhabdomyolysis risk (especially in overdose or combined with statins or high-dose diuretics); myoglobin released from destroyed muscle is directly nephrotoxic — a leading hospital cause of AKI.
Clozapine (Clozaril)
Rhabdomyolysis risk; also SIADH (water retention causing dilutional hyponatremia and osmotic stress on renal cells).
Statins — Rhabdomyolysis & Myoglobin-Induced Tubular Injury
Rhabdomyolysis (skeletal muscle breakdown) releases myoglobin into the bloodstream; myoglobin is directly nephrotoxic, causing tubular obstruction and oxidative damage. CYP3A4 inhibitors (many common drugs, grapefruit) dramatically increase statin blood levels and rhabdomyolysis risk. Statins are universally prescribed in CKD/cardiovascular patients.
Simvastatin (Zocor)
Highest rhabdomyolysis risk of common statins at higher doses; 80mg dose withdrawn from guidelines after multiple rhabdomyolysis deaths.
Atorvastatin (Lipitor)
Most prescribed statin worldwide; rhabdomyolysis risk lower than simvastatin but not absent; CYP3A4 metabolism means drug interactions elevate levels significantly.
Rosuvastatin (Crestor)
Not CYP3A4 metabolized — fewer drug interactions; but dose accumulates in CKD; associated with proteinuria and hematuria at higher doses.
Lovastatin (Mevacor)
CYP3A4 metabolized; higher rhabdomyolysis risk with CYP inhibitors (azole antifungals, macrolides, grapefruit).
Other Commonly Prescribed Nephrotoxins
Metformin (Glucophage, Glumetza)
Not directly nephrotoxic — but causes fatal lactic acidosis when eGFR falls below 30 (kidneys cannot clear lactic acid). Contraindicated below eGFR 30, requires dose reduction below eGFR 45. Still prescribed to CKD patients without eGFR check. FDA issued strengthened warning in 2016 after continuing to be prescribed in severe CKD.
Allopurinol (Zyloprim, Aloprim)
Used for gout — which is itself a cause of CKD. Allopurinol hypersensitivity syndrome causes severe AIN; xanthine crystals can deposit in tubules at high doses; dose reduction required in CKD, infrequently performed.
Colchicine (Colcrys)
Accumulates significantly in CKD; in overdose or accumulation causes rhabdomyolysis — adding the myoglobin-AKI pathway on top of existing kidney compromise. Dose reduction required in CKD; not consistently applied.
Penicillamine (Cuprimine, Depen)
Used in Wilson's disease and rheumatoid arthritis; causes membranous nephropathy through immune complex deposition on the glomerular basement membrane.
Gold salts (Myochrysine — historical RA treatment)
Membranous nephropathy; largely replaced by DMARDs but still occasionally used; proteinuria was a recognized side effect rarely disclosed.
Sodium phosphate bowel prep (Fleet Phospho-Soda, OsmoPrep)
Oral sodium phosphate used for colonoscopy prep causes acute phosphate nephropathy — phosphate crystal deposits in renal tubules. FDA issued Black Box Warning in 2008. Polyethylene glycol-based preps are safer; sodium phosphate is still used. Risk dramatically higher in CKD patients, who often need colonoscopy.
Aristolochic acid (in some traditional herbal products — not FDA approved)
Causes aristolochic acid nephropathy — severe progressive CKD and high risk of urothelial cancer. Found in some traditional Chinese and Ayurvedic herbal preparations. Banned in many countries; still available in some supplements and teas. Patients using herbal products while on dialysis workup are rarely asked about this.
OTC Medications — Antihistamines, Decongestants, Antacids, Pain Relievers
Over-the-counter does not mean kidney-safe. Because these drugs are available without a prescription, patients often take them daily for years without medical oversight, and they are rarely disclosed in medication reviews or nephrology intake assessments.
Diphenhydramine (Benadryl, ZzzQuil, Unisom, Tylenol PM, Advil PM)
First-generation antihistamine — anticholinergic. Urinary retention from anticholinergic effects increases bladder pressure and back-pressure on kidneys; chronic urinary retention causes obstructive nephropathy. Accumulates in CKD patients — causes confusion, sedation, and falls at lower doses than in healthy adults. Widely used as a sleep aid in older adults. Multiple geriatric guidelines list it as inappropriate in the elderly (Beers Criteria) — rarely communicated by pharmacists. Found in most combination PM pain/sleep products alongside acetaminophen or ibuprofen, adding the NSAID or hepatotoxic load on top.
Loratadine (Claritin, Alavert)
Second-generation antihistamine — renally cleared; dose reduction required when eGFR <30 (recommended dosing: every 48 hours instead of daily). In practice this adjustment is almost never made. Claritin-D (with pseudoephedrine) adds vasoconstriction to the picture.
Cetirizine (Zyrtec)
Second-generation antihistamine — primarily renally eliminated (70% excreted unchanged in urine). Significantly accumulates in CKD: half-life extends from ~8 hours (normal) to ~20 hours (eGFR 11–31) to ~30+ hours (dialysis). Dose adjustment required; not communicated on OTC labeling. Daily use in CKD = progressive drug accumulation with each dose.
Fexofenadine (Allegra)
Second-generation antihistamine; primarily eliminated in feces, not urine — better tolerated in CKD than cetirizine/loratadine. Still requires dose reduction in severe renal impairment. The OTC packaging does not distinguish between normal and CKD dosing.
Pseudoephedrine (Sudafed, in Claritin-D, Zyrtec-D, Allegra-D)
Decongestant — sympathomimetic that causes vasoconstriction systemically including in renal vasculature. Raises blood pressure; reduces renal blood flow. Should be avoided in hypertension and CKD — rarely communicated. Renally eliminated; accumulates in CKD. The "-D" formulations combine antihistamine accumulation with renal vasoconstriction.
Phenylephrine (Sudafed PE, DayQuil, NyQuil, many combination cold products)
Decongestant — alpha-1 agonist causing vasoconstriction; raises blood pressure; reduces renal perfusion. FDA advisory committee ruled in 2023 that oral phenylephrine is not effective as a decongestant at OTC doses — it is still sold in dozens of combination cold products despite the ruling. The vasoconstriction it causes is real even if the decongestant effect is not.
Acetaminophen — long-term high-dose (Tylenol, in hundreds of combination products)
Chronic high-dose acetaminophen use (consistently 2g+/day for years) is associated with analgesic nephropathy — renal papillary necrosis and chronic interstitial nephritis — particularly when combined with aspirin or caffeine (the historical APC tablet combination). Acute overdose causes liver failure via NAPQI mechanism. OTC labeling does not adequately communicate that long-term daily use at the maximum daily dose is nephrotoxic, or that it is present in dozens of combination products simultaneously (PM sleep aids, cold medications, prescription opioid combinations like Vicodin and Percocet).
Calcium carbonate antacids (Tums, Rolaids, Caltrate)
Widely used for heartburn and as calcium supplements. In CKD, impaired phosphate clearance already drives secondary hyperparathyroidism; adding a daily calcium carbonate load elevates calcium further, accelerating vascular calcification. Milk-alkali syndrome (hypercalcemia, alkalosis, AKI from calcium carbonate overuse) is a recognized — and underdiagnosed — cause of acute kidney injury, historically seen with dairy + antacid combinations, now re-emerging with calcium supplement use. Patients with CKD are often told to take calcium for bone health without awareness of the vascular calcification risk.
Magnesium-containing antacids and laxatives (Milk of Magnesia, Maalox, Rolaids — some formulations)
Magnesium is renally cleared. In healthy individuals, excess magnesium is readily excreted. In CKD patients (eGFR <30), magnesium accumulates rapidly — causing hypermagnesemia: hypotension, respiratory depression, cardiac arrhythmia, and neuromuscular blockade at high levels. Patients taking OTC magnesium laxatives or antacids in the context of CKD are at significant risk. Pharmacists do not typically flag this. The patient does not know their kidneys cannot clear the magnesium load from a "gentle" OTC laxative.
Sodium-containing antacids and effervescent products (Alka-Seltzer, some Bromo Seltzer formulations)
Alka-Seltzer Original contains 567 mg sodium per tablet (2 tablets = over 1,100 mg sodium). For a patient on a 2g/day sodium restriction for CKD or heart failure, a single dose exceeds half the daily sodium budget. Sodium accumulation drives fluid retention, hypertension, and increased cardiac and renal stress. Patients using Alka-Seltzer for hangover or indigestion are not reading the sodium content — and their cardiologist and nephrologist are not asking about it.
Fluoride — Water & Fluorinated Drugs
Renal tubular accumulation and fluoroquinolone nephrotoxicity
The kidneys are the primary route of fluoride excretion. In CKD, fluoride clearance is impaired — fluoride accumulates at higher levels than in healthy individuals. Fluoride at elevated concentrations is directly toxic to renal tubular epithelial cells. In communities with fluoridated water at standard levels (0.7 ppm), the kidneys in a healthy person excrete the load adequately; in reduced kidney function, the same exposure creates accumulation. This is not discussed when CKD is diagnosed.
Fluoroquinolone antibiotics — ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin:
Fluorinated compounds independently associated with acute kidney injury via AIN and direct tubular injury. Covered individually in the drug list above. Key point here: the fluorine atom in these drugs releases inorganic fluoride during metabolism — the same species toxic to renal tubular cells — adding a dual nephrotoxic mechanism (drug class AIN + fluoride tubular toxicity) that is not disclosed when prescribed.
Historically: Methoxyflurane, a fluorinated anesthetic used in the 1960s–70s, caused high-output renal failure through inorganic fluoride release, leading to its withdrawal. The fluoride-kidney connection in pharmaceuticals is mechanistically established. It is simply not part of the conversation when fluorinated drugs are prescribed today.
Caffeine, Coffee & Chronic Dehydration
Not just caffeine — the coffee plant as a pesticide-laden alkaloid source
Caffeine inhibits adenosine receptors and promotes renal sodium and water excretion. It also causes afferent arteriolar vasoconstriction, transiently reducing glomerular blood flow. In a person consuming caffeine multiple times per day, every day, for years — without consistently replacing fluid — this creates a pattern of mild but chronic renal underperfusion. Caffeine also raises plasma renin activity and increases angiotensin II, compounding vasoconstriction in patients who are already hypertensive.
Coffee beyond the caffeine — what the plant itself contains
Coffee is one of the most heavily sprayed crops in the world. The majority of commercial coffee is grown in countries with fewer pesticide restrictions than the US or EU, using organophosphates, chlorpyrifos, endosulfan, and other agrochemicals that are restricted or banned in many developed nations. These residues are concentrated during the roasting and brewing process and are renally cleared in the consumer.
Alkaloids beyond caffeine: Coffee contains chlorogenic acids, trigonelline, cafestol, and kahweol — diterpene compounds concentrated in unfiltered coffee (French press, espresso, Turkish coffee). Cafestol and kahweol are among the most potent dietary elevators of LDL cholesterol known; they also place metabolic demands on hepatic and renal clearance pathways. Paper-filtered coffee removes most diterpenes; unfiltered does not.
Ochratoxin A in coffee: Commercial coffee beans — particularly pre-ground coffee — are frequently contaminated with ochratoxin A (OTA), the mold mycotoxin detailed in the industrial toxins section. OTA survives roasting at standard temperatures. A 2013 analysis found OTA in 33% of green coffee samples and 27% of roasted coffee. Coffee is one of the primary dietary sources of ochratoxin A exposure in Western populations — adding a direct tubular nephrotoxin to the already dehydrating, vasoconstrictive, and pesticide-laden profile.
Fluoride in black and green tea: Tea plants (Camellia sinensis) hyperaccumulate fluoride from soil, with mature leaves containing significantly more than young leaves. A single cup of black tea brewed for 5 minutes can contain 1–5 mg fluoride — comparable to a glass of fluoridated water. People drinking 3–4 cups of tea daily are adding meaningful fluoride exposure to their existing load, renally cleared, accumulating in CKD patients.
Disposable coffee cups — plastic you drink: Single-use paper cups used by virtually every coffee shop are lined with polyethylene plastic film — what makes them liquid-resistant. When filled with hot coffee, this lining releases microplastic particles and plastic chemical compounds directly into the beverage. A 2021 study found that a standard hot beverage in a paper cup leached approximately 25,000 microplastic particles into the drink within 15 minutes of contact. One to three disposable-cup coffees per day adds a consistent microplastic and plastic chemical load to every cup — stacking on top of the pesticide, alkaloid, and mycotoxin profile already described.
Concentrated urine + kidney stones: Chronic caffeine-driven mild dehydration increases urine concentration, promoting crystallization of calcium oxalate and uric acid — the two most common kidney stone types. Kidney stones cause direct tubular obstruction and scar formation with each episode. A history of kidney stones is a risk factor for CKD that is rarely connected to the caffeine intake that preceded them.
Alcohol
Direct tubular toxicity, dehydration, hypertension, and uric acid
Alcohol suppresses antidiuretic hormone (ADH), causing the kidneys to excrete more fluid than is consumed. This acute dehydrating effect is well known. Less discussed: chronic alcohol use impairs the tubular transport mechanisms responsible for reabsorbing glucose, amino acids, phosphate, and magnesium — driving electrolyte imbalances that stress multiple organ systems, including the kidney itself.
Alcohol drives hypertension through multiple pathways — sympathetic nervous system activation, renin-angiotensin system stimulation, and direct vasoconstriction. Hypertension is the second leading cause of ESRD. The role of alcohol in sustaining the hypertension that eventually destroys kidney function is not part of the CKD conversation.
Uric acid and gout: Alcohol impairs renal uric acid excretion and increases uric acid production, particularly beer (purines) and spirits. Elevated uric acid is an independent risk factor for CKD and drives urate crystal deposition in renal tubules. Gout — a condition closely associated with alcohol — is a recognized pathway to progressive kidney disease that is almost never framed that way in clinical conversations.
Vaccines — Aluminum Adjuvants & Post-Vaccination Kidney Conditions
Aluminum is cleared by the kidneys — in CKD, it accumulates
The primary route of aluminum excretion from the body is renal. In healthy kidneys, aluminum injected via vaccine adjuvant is cleared over time. In CKD and ESRD, this clearance is severely impaired. Aluminum accumulates in bone, brain, and other tissues — a fact established by the dialysis dementia epidemic of the 1970s–80s when aluminum-containing phosphate binders were routinely given to dialysis patients. Those binders were eventually discontinued in this population for exactly this reason. Aluminum-adjuvant vaccines are still routinely administered to the same population without the same concern being raised.
The aluminum clearance problem in CKD
Aluminum toxicity in dialysis patients was well documented before aluminum phosphate binders were removed from use in this population. The consequences: dialysis dementia (progressive encephalopathy), aluminum bone disease (adynamic bone, pathological fractures), and microcytic anemia unresponsive to iron. These were caused by chronic aluminum accumulation in patients whose kidneys could not clear it.
Aluminum-adjuvant vaccines inject the same element — aluminum hydroxide, aluminum phosphate, or AAHS — directly into muscle tissue, where macrophages transport it systemically. In a patient with eGFR below 30, the pharmacokinetics of aluminum clearance are the same as they were in the patients who developed dialysis dementia. This is not discussed when scheduling routine vaccines for CKD or dialysis patients.
Aluminum adjuvant types:
Al(OH)₃ = aluminum hydroxide · AlPO₄ = aluminum phosphate · AAHS = amorphous aluminum hydroxyphosphate sulfate · AS04 = aluminum hydroxide + MPL (a toll-like receptor agonist). Aluminum content figures are per dose from manufacturer package inserts.
DTaP / Tdap — Diphtheria, Tetanus, Pertussis
Infanrix (GlaxoSmithKline — DTaP)
Adjuvant: Al(OH)₃ — 625 mcg aluminum per dose. Infant series: 3 primary doses at 2, 4, 6 months + boosters at 15–18 months and 4–6 years = 5 doses = up to 3,125 mcg aluminum in the first 6 years of life.
Daptacel (Sanofi — DTaP)
Adjuvant: AlPO₄ — 330 mcg aluminum per dose. 5-dose infant/childhood series = 1,650 mcg aluminum total from this vaccine alone.
Pediarix (GSK — DTaP + HepB + IPV combined)
Adjuvant: Al(OH)₃ + AlPO₄ — 850 mcg aluminum per dose. 3-dose primary series = 2,550 mcg aluminum; replaces both standalone DTaP and Hepatitis B vaccine doses.
Pentacel (Sanofi — DTaP + Hib + IPV combined)
Adjuvant: AlPO₄ — 1,500 mcg aluminum per dose. Highest aluminum dose of the DTaP combinations. 4-dose primary series = 6,000 mcg aluminum.
Adacel (Sanofi — Tdap adult booster)
Adjuvant: AlPO₄ — 330 mcg aluminum per dose.
Boostrix (GSK — Tdap adult booster)
Adjuvant: Al(OH)₃ + AlPO₄ — 390 mcg aluminum per dose.
Tdap in Pregnancy — Every Pregnancy, 27–36 Weeks
Since 2013, the CDC has recommended Tdap during every pregnancy, at 27–36 weeks gestation — not once per lifetime, but once per pregnancy. The rationale is passive antibody transfer to the newborn before the infant can complete their own series.
What this means in terms of aluminum exposure:
This is in addition to the standard childhood DTaP series and the standard adult Tdap booster every 10 years. A woman who received the full childhood series (5 DTaP doses), the standard adult booster, and 3 pregnancy doses has received Tdap aluminum alone — not counting any other aluminum-adjuvant vaccines — across her lifetime. All of it cleared renally.
The fetal side: Aluminum injected into the mother during pregnancy crosses the placenta. Fetal kidneys are not mature — they begin producing urine by week 16 but fetal glomerular filtration rate is a fraction of adult capacity. The aluminum reaching the fetus via placental transfer is not efficiently cleared. Long-term studies of aluminum accumulation in children born to mothers who received Tdap during pregnancy have not been conducted.
The 2013 policy change from "once per lifetime" to "once per pregnancy" was made without long-term studies on cumulative maternal or fetal aluminum burden. The package inserts for both Adacel and Boostrix state that available data on use in pregnancy are insufficient to inform vaccine-associated risks — and both state the vaccine was not studied for effects on fertility or fetal development at the time of approval for use in pregnancy.
Hepatitis B
Hepatitis B vaccination is specifically recommended for all CKD and dialysis patients — making aluminum clearance in this population directly relevant. A 3-dose or 4-dose accelerated series is standard in dialysis.
Engerix-B (GlaxoSmithKline)
Adjuvant: Al(OH)₃ — 500 mcg aluminum per dose (adult). 3-dose series = 1,500 mcg total aluminum, cleared entirely by kidneys that are no longer functioning adequately.
Recombivax HB (Merck)
Adjuvant: AAHS — 250 mcg aluminum per adult dose; 500 mcg per dialysis-specific dose (Recombivax HB Dialysis Formulation uses a higher antigen and AAHS dose).
Heplisav-B (Dynavax)
Adjuvant: CpG 1018 (cytosine-phosphoguanine oligonucleotide — a TLR9 agonist). No aluminum adjuvant. 2-dose series. The only currently licensed hepatitis B vaccine in the US without aluminum — relevant context for this conversation.
Twinrix (GSK — Hep A + Hep B combined)
Adjuvant: Al(OH)₃ + AlPO₄ — 450 mcg aluminum per dose. Combines both hepatitis vaccines into one injection; aluminum content adds both components.
Hepatitis A
Havrix (GlaxoSmithKline)
Adjuvant: Al(OH)₃ — 500 mcg aluminum per adult dose (250 mcg pediatric). 2-dose series.
Vaqta (Merck)
Adjuvant: AAHS — 450 mcg aluminum per adult dose (225 mcg pediatric). 2-dose series.
HPV — Human Papillomavirus
Gardasil 9 (Merck — 9-valent HPV)
Adjuvant: AAHS — 500 mcg aluminum per dose. 2-dose series (ages 9–14) or 3-dose (ages 15+). Total aluminum: 1,000–1,500 mcg per series, cleared entirely renally.
Cervarix (GSK — bivalent HPV; withdrawn from US market)
Adjuvant: AS04 — Al(OH)₃ 500 mcg + MPL 50 mcg per dose. AS04 is a dual adjuvant using both aluminum and a toll-like receptor agonist simultaneously.
Pneumococcal Conjugate
Prevnar 13 (Pfizer — PCV13)
Adjuvant: AlPO₄ — 125 mcg aluminum per dose. Standard recommendation for adults over 65 and immunocompromised patients including CKD.
Prevnar 20 (Pfizer — PCV20)
Adjuvant: AlPO₄ — 250 mcg aluminum per dose. Expanded valency; replacing PCV13 in adult schedules.
Meningococcal B
Bexsero (GSK — MenB-4C)
Adjuvant: Al(OH)₃ — 500 mcg aluminum per dose. 2-dose series = 1,000 mcg total aluminum.
Trumenba (Pfizer — MenB-FHbp)
Adjuvant: AlPO₄ — 250 mcg aluminum per dose. 2 or 3-dose series.
Hib — Haemophilus influenzae type b
PedvaxHIB (Merck)
Adjuvant: AAHS — 225 mcg aluminum per dose. Other Hib vaccines (ActHIB, Hiberix) use no aluminum adjuvant — relevant contrast.
Anthrax
BioThrax (Emergent BioSolutions)
Adjuvant: Al(OH)₃ — 1,200 mcg aluminum per dose. Highest single-dose aluminum content of any licensed US vaccine. 5-dose pre-exposure series. Used in military and at-risk laboratory workers.
No Aluminum Adjuvant — For Reference
These vaccines use alternative adjuvant systems or no adjuvant — relevant when discussing options with CKD patients who are being scheduled for immunization.
COVID-19 mRNA vaccines (Pfizer-BioNTech, Moderna)
No aluminum adjuvant. Lipid nanoparticle (LNP) delivery system. Other safety questions documented in the literature; aluminum accumulation is not one of them.
Shingrix (GSK — shingles)
Adjuvant: AS01B — MPL + QS-21 saponin. No aluminum. IgA nephropathy flares have been reported post-Shingrix; adjuvant system still stimulates immune response. Routinely given to CKD/dialysis patients.
Influenza — standard formulations (Fluzone, Flucelvax, Flublok)
No aluminum adjuvant in standard US flu vaccines. Fluad (Seqirus) uses MF59 squalene adjuvant — no aluminum. Routinely given annually to dialysis patients.
Other vaccine components with kidney relevance
Beyond aluminum, the following components in vaccine formulations have documented or mechanistically relevant effects on kidney function — particularly in patients with CKD whose clearance is already impaired.
Thimerosal (ethylmercury — still in multi-dose flu vaccines)
Mercury is a direct nephrotoxin — proximal tubular cells are the primary site of mercury accumulation and damage. Inorganic mercury inhibits tubular reabsorption and disrupts mitochondrial function in tubular cells. Thimerosal was removed from most childhood vaccines in 2001 but remains in multi-dose influenza vials, which are still routinely used in dialysis centers and hospital settings. Dialysis patients receiving annual flu shots from multi-dose vials receive mercury injection with no kidney monitoring.
Aminoglycoside residuals (neomycin, gentamicin, streptomycin — manufacturing residuals)
Aminoglycosides are used during vaccine production to prevent bacterial contamination; residuals remain in the final product. Neomycin is present in MMR, varicella (Varivax), and some IPV formulations. Gentamicin in FluMist and some influenza vaccines. Streptomycin in some IPV vaccines. These are the same drugs that require therapeutic drug monitoring and trough levels when given intravenously due to direct proximal tubular toxicity. Injected as vaccine residuals, they bypass intestinal absorption entirely and enter the bloodstream directly — the most bioavailable route for kidney exposure. No monitoring is performed.
Polysorbate 80 (surfactant/emulsifier — DTaP, HPV, influenza, and many others)
Polysorbate 80 is a surfactant that increases membrane permeability — it is used in pharmaceutical drug delivery research specifically because it facilitates penetration of biological barriers including the blood-brain barrier. In the context of kidney function: polysorbate 80 may enhance the cellular uptake of co-injected components (including aluminum particles and residual proteins) into renal tubular cells. It is present in numerous vaccines and the combined systemic effect of repeated administration in CKD patients — whose clearance is already impaired — has not been studied.
Formaldehyde (viral/toxin inactivation residual — IPV, DTaP, hepatitis A, influenza, and others)
Formaldehyde is used to inactivate viruses and bacterial toxins during vaccine production; residuals remain in the final product. Orally ingested formaldehyde undergoes hepatic first-pass detoxification before reaching systemic circulation. Injected formaldehyde bypasses this entirely, entering systemic circulation directly. The kidneys are a primary route of formaldehyde metabolite excretion. Cumulative exposure across the childhood immunization schedule has not been formally studied for kidney-specific outcomes.
HEK-293 cell line residuals (human embryonic kidney cells — used in some COVID-19 vaccine production and testing)
HEK-293 is a human embryonic kidney cell line used in the production or testing of some vaccines, including the adenoviral vector COVID-19 vaccines. Residual cellular proteins and DNA from the production cell line can remain in the final product. The immune relevance: in a patient with autoimmune kidney disease or existing glomerulonephritis, residual proteins derived from human kidney cells could theoretically contribute to immune cross-reactivity targeting renal tissue. This has not been systematically studied.
MDCK & Vero cell line residuals (canine kidney and African Green Monkey kidney cells — influenza, IPV, rabies)
MDCK (Madin-Darby Canine Kidney) cells are used in the production of FluMist and some injectable influenza vaccines. Vero cells (African Green Monkey kidney cells) are used in IPV (inactivated polio), rabies, and some other vaccines. Both are kidney-derived cell lines. Residual non-human kidney cell proteins and DNA in the final vaccine product represent a xenobiotic antigen load that the immune system must process — and in patients with existing immune-mediated kidney disease, the immune response to these residuals has not been characterized.
PEG — polyethylene glycol (lipid nanoparticle stabilizer — Pfizer, Moderna COVID-19 vaccines)
PEG is the stabilizing polymer in the mRNA vaccine lipid nanoparticle (LNP) formulation. PEG is renally excreted; in CKD, PEG clearance is impaired and it accumulates. High-molecular-weight PEG accumulation has been associated with osmotic nephrosis — vacuolization of proximal tubular cells — a finding documented with PEG-containing IV formulations in compromised kidneys. Anaphylactic reactions to PEG have been documented; the kidney consequences of PEG accumulation in CKD patients receiving mRNA vaccines have not been studied.
Post-vaccination kidney conditions documented in the literature
Membranous nephropathy — hepatitis B vaccine
First described in 1989; antibody-antigen immune complex deposits on the glomerular basement membrane. Mechanism: immune complex deposition from the vaccine antigen-antibody response. Given the hepatitis B series is specifically recommended for all dialysis patients, the temporal association is particularly relevant in this population.
IgA nephropathy exacerbation — multiple vaccines
IgA nephropathy flares in response to immune stimulation events including vaccination. Documented following influenza, COVID-19 (mRNA and vector), and hepatitis B vaccines. Patients with existing IgA nephropathy are not routinely warned of flare risk before vaccination.
Minimal change disease and FSGS — COVID-19 mRNA vaccines
New-onset minimal change disease and focal segmental glomerulosclerosis (FSGS) documented in case series following COVID-19 mRNA vaccination. Immune-mediated podocyte injury — not predicted by pre-market trials. VAERS and international pharmacovigilance databases contain consistent signals across independent reporters.
ANCA-associated vasculitis — COVID-19 vaccines
Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis — including crescentic glomerulonephritis — has been reported following COVID-19 mRNA and adenoviral vector vaccines. ANCA vasculitis can cause rapid, severe loss of kidney function and was one of the more serious post-vaccination renal signals in the literature.
RhoGAM (Rh Immunoglobulin) — Cumulative Mercury Exposure Across Pregnancies
Given at 28 weeks and again after every Rh-positive delivery
RhoGAM is Rh(D) immunoglobulin — a blood product derived from human plasma, given to Rh-negative mothers to prevent sensitization to Rh-positive fetal blood cells. The standard protocol is two doses per pregnancy: one antepartum dose at 28 weeks (before the baby's blood type is confirmed) and one postpartum dose within 72 hours of delivery if the baby tests Rh-positive. A woman with multiple pregnancies receives this protocol repeatedly — and with it, repeated exposures to thimerosal and other components that are renally cleared.
What patients are told
"Your blood is Rh-negative. The baby may be Rh-positive. This shot prevents your immune system from attacking future pregnancies."
What isn't said
The product contains thimerosal (or trace mercury even in labeled "thimerosal-free" formulations), polysorbate 80, and human albumin — and is given before the baby's blood type is known, meaning some doses are administered to women whose babies will turn out to be Rh-negative.
Thimerosal & Trace Mercury — What "Thimerosal-Free" Actually Means
Multi-dose vials (some formulations still in use): Contain thimerosal as a preservative at approximately 25 mcg ethylmercury per dose.
"Thimerosal-free" single-dose formulations (RhoGAM Ultra-Filtered Plus, HyperRHO S/D, WinRho SDF): Labeled thimerosal-free because thimerosal was not added as a preservative. However, FDA labeling standards allow "thimerosal-free" when residual mercury from manufacturing is below a threshold — typically <0.3 mcg per dose. Trace mercury is present. This is disclosed in the package insert but not communicated verbally to patients.
Ethylmercury vs. methylmercury: Ethylmercury (in thimerosal) is metabolized and cleared faster than methylmercury (in fish). It is still nephrotoxic — proximal tubular cells are a primary site of mercury accumulation regardless of the organic mercury form. In pregnant women, mercury crosses the placenta. Fetal kidneys at 28 weeks are not capable of efficient mercury clearance.
Cumulative mercury exposure — standard 2-dose protocol per Rh+ pregnancy
Figures below use 25 mcg/dose for multi-dose thimerosal-containing formulations. Trace-mercury "thimerosal-free" formulations: add <0.3 mcg/dose. In clinical practice, patients are rarely told which formulation they are receiving.
The 28-week dose is given before the baby's blood type is known
The antepartum RhoGAM dose at 28 weeks is given universally to all Rh-negative mothers — before fetal blood typing. Approximately 40% of Rh-negative women carry Rh-negative babies (depending on the father's genotype), meaning the postpartum dose would not be necessary for those pregnancies. Non-invasive fetal Rh genotyping from maternal blood is available in several countries (UK, Netherlands, Denmark) as standard of care, allowing Rh-negative mothers carrying Rh-negative fetuses to avoid the antepartum dose. This approach is not standard practice in the United States. The antepartum dose continues to be given regardless of fetal blood type.
What happens when Rh-positive material is injected into an Rh-negative immune system
The immune activation RhoGAM is designed to prevent — and what repeated exposure means
An Rh-negative person's immune system has no prior exposure to the Rh(D) antigen — a protein found on red blood cell surfaces in Rh-positive individuals. When Rh-positive fetal blood cells enter the maternal circulation (during delivery, miscarriage, or invasive procedure), the Rh-negative immune system recognizes the D antigen as foreign and begins producing anti-D antibodies. In a subsequent Rh-positive pregnancy, these antibodies cross the placenta and attack fetal red blood cells — hemolytic disease of the newborn.
RhoGAM works by introducing passive anti-D antibodies that bind to any Rh-positive fetal cells in maternal circulation before the mother's own immune system can mount a primary response — essentially blocking sensitization. The immune mechanism is suppression of the primary immune response, not enhancement. In this framing, RhoGAM is not a vaccine in the conventional sense.
What the package insert states about administration to the wrong patient:
If RhoGAM is administered to an Rh-positive individual — or to anyone with Rh-positive red blood cells already in circulation — the passive anti-D antibodies cause hemolysis of those cells. Documented reactions include: fever, back and flank pain (from hemoglobin released by lysed cells damaging tubular epithelium), nausea, vomiting, hypotension, hemoglobinuria, elevated serum creatinine, and decreased haptoglobin. The creatinine elevation and hemoglobinuria are direct indicators of acute kidney involvement — myoglobin/hemoglobin-induced tubular injury, the same pathway as rhabdomyolysis. Screening to confirm the patient is truly Rh-negative before administration is required but errors occur.
Repeated immune stimulation: Each RhoGAM injection introduces approximately 300 mcg of human immunoglobulin G derived from pooled donor plasma. The reticuloendothelial system processes these antibodies. In women with multiple pregnancies receiving multiple rounds of RhoGAM, the cumulative immune activation from repeated foreign immunoglobulin introduction — alongside the mercury, polysorbate 80, and other excipients — has not been studied as an aggregate. Each dose is evaluated individually in trials; the multi-dose, multi-pregnancy cumulative burden is not.
Other RhoGAM components
EMF — Non-Native Electromagnetic Fields
Oxidative stress on renal tubular cells and disrupted nocturnal kidney repair
The kidneys are metabolically active, oxygen-dependent organs. They have a documented circadian rhythm — filtration rate, sodium excretion, and tubular repair all follow a nocturnal pattern coordinated by the autonomic nervous system and the circadian clock. Disruption of this cycle impairs the repair capacity that the kidney relies on during sleep.
Research on electromagnetic field exposure and renal function is more extensive than the clinical world acknowledges. Multiple animal studies and at least one human epidemiological study document kidney damage from EMF exposure at levels relevant to daily life. The mechanisms are multiple and documented — this is not speculative.
BUN and creatinine elevation — 900/1800 MHz and 2400 MHz exposure (multiple animal studies)
Blood urea nitrogen and serum creatinine — the same markers used to assess kidney function in clinical practice — are elevated following EMF exposure in multiple animal studies at 900, 1800, and 2400 MHz. These are the frequencies of cellular networks and WiFi, not industrial equipment.
4G cell phone radiation — kidney interstitial inflammation and creatinine increase (mice, 60-minute exposures)
A published study on 4G cell phone radiation in mice showed increased serum creatinine and kidney interstitial inflammation with mononuclear cellular infiltration — an immune-mediated inflammatory pattern in kidney tissue — after 60-minute exposures. The exposure duration used in the study is within the range of daily phone use.
Tubular epithelial cell swelling and necrosis — 5 Hz and 50 Hz ELF-EMF (guinea pig, 4 hrs/day)
At extremely low frequencies (5 Hz at 0.013 µT and 50 Hz at 0.207 µT — below levels emitted by common household wiring), 4 hours/day exposure caused epithelial cells of renal tubules to swell and undergo necrosis, decreasing tubular lumens. The 50 Hz frequency is the frequency of standard electrical current in Europe and most of the world; 60 Hz in North America.
2100 MHz postnatal exposure — pathological kidney findings in male rats
2100 MHz is the frequency of 3G networks. Postnatal male rat exposure produced documented pathological findings in kidney tissue. 2100 MHz exposure during development — when kidneys are maturing — produced histological kidney changes.
Mobile phone use and new-onset CKD in humans — International Journal of Public Health
A human epidemiological study published in the International Journal of Public Health found mobile phone use significantly associated with higher risk of new-onset chronic kidney disease, with risk increasing with longer weekly usage. This is a human outcome study — not an animal model — showing the CKD association with phone use in the population.
Renin-angiotensin system alteration from pre/postnatal 900 MHz exposure
Pre- and postnatal exposure to 900 MHz EMF alters components of the renin-angiotensin system — the hormonal system that regulates blood pressure and kidney filtration pressure — differently in male and female offspring. The RAS governs glomerular filtration rate; its dysregulation from early EMF exposure represents a developmental pathway to CKD.
Martin Pall's VGCC mechanism → nitric oxide → renal vasoconstriction
EMF activates voltage-gated calcium channels (VGCCs), causing excessive intracellular calcium that generates nitric oxide and peroxynitrite. High inducible nitric oxide (iNOS) simultaneously inhibits endothelial NOS — reducing the nitric oxide that maintains vascular tone. The result is renal vasoconstriction and reduced GFR — the same mechanism that NSAIDs produce via prostaglandin blockade. VGCC effects on kidney vasculature have been demonstrated to be blockable by calcium channel blockers, confirming the mechanism.
Electric field effects on renal tubular cell ion channels and membrane transport
Research on human renal tubular epithelial cells shows that electric fields directly redistribute ion transport proteins (NaKA, NHE3) and receptors (AchR, NMDAR) at the cell membrane level, altering the normal polarity and transport function of tubular epithelium. The tubule's ability to reabsorb glucose, phosphate, amino acids, and other essential solutes depends on this membrane polarity — disruption of which is the hallmark of Fanconi syndrome and tubular dysfunction.
WiFi router in the bedroom or workspace
A home WiFi router operating at 2.4 GHz or 5 GHz within close proximity (under 10 feet) produces continuous RF exposure that does not cease during sleep. For someone sleeping with a router in the bedroom or working 3–4 feet from one for 8–10 hours/day, this represents sustained low-level RF exposure to the torso and kidneys across years. Moving the router out of the bedroom costs nothing and is the simplest first step.
Phone in pocket
A smartphone in a front or back pants pocket is held against the hip and lower abdomen for hours daily — directly adjacent to the kidneys, reproductive organs, and liver. The phone transmits whenever it is connected to cellular, WiFi, or Bluetooth networks — including while in the pocket. This is not theoretical: the fine print in phone manufacturer safety guidelines specifies minimum separation distances from the body (typically 5–15 mm) that are violated when a phone is carried in clothing.
Bluetooth keyboard and mouse — working next to router
Bluetooth operates at 2.4 GHz — the same frequency as microwave ovens, though at far lower power. Using a Bluetooth keyboard and mouse while also working next to a WiFi router creates layered RF sources at close range for the duration of the workday. Wired keyboard and mouse eliminate this source entirely. Placing the router across the room or in a different room significantly reduces exposure.
CPAP machine next to the head during sleep
Modern CPAP machines — particularly those with WiFi or Bluetooth for remote monitoring (ResMed AirSense series, Philips DreamStation) — transmit wirelessly through the night. The machine sits 12–24 inches from the head for 6–8 hours nightly. If the wireless transmission feature is active, this is one of the highest-proximity, longest-duration EMF exposures in daily life. Disabling WiFi/Bluetooth on CPAP devices is possible but rarely communicated to patients. For the sleep apnea patient whose kidneys need nocturnal repair, this is a relevant variable.
High-EMF vehicles — including electric vehicles
Electric vehicles produce significant magnetic field exposure from the battery pack and drive motor, particularly at the floor level where seated occupants are positioned. Gasoline-powered vehicles also produce EMF from the alternator and ignition system, with variation by model. For someone commuting 1–2 hours daily, this represents meaningful daily exposure that accumulates over years. This is not routinely measured or disclosed by manufacturers.
The kidney-sleep-EMF connection
The kidney follows a circadian rhythm governed by the same clock mechanisms disrupted by artificial light, WiFi, and screen exposure at night. Nocturnal blood pressure should drop 10–20% during sleep ("dipping") — a process essential for renal recovery and repair. In poor sleepers and those with circadian disruption, this dipping is impaired or absent. Sustained overnight hypertension, even mild, accelerates nephron loss over years. EMF is one of several inputs — alongside blue light, WiFi, and device use — that blunts this protective nocturnal dip.
Poor Sleep & Sleep Apnea
Nocturnal hypoxia, sustained overnight pressure, and impaired tubular repair
Sleep apnea causes repeated nocturnal hypoxemia — oxygen drops during each apneic event. The kidneys, which require consistent oxygen delivery to maintain tubular cell function, experience repeated ischemic stress across every night of untreated apnea. Proteinuria — protein leaking into urine, a marker of glomerular damage — is more prevalent in sleep apnea patients and can improve with CPAP treatment.
The nocturnal blood pressure drop that protects the kidney (the "dipping" pattern) is absent or blunted in sleep apnea patients. Non-dippers have significantly faster progression of CKD than dippers, independent of daytime blood pressure control. A patient whose daytime blood pressure is "controlled" on medication but who is a non-dipper due to sleep apnea is receiving inadequate protection for their kidneys overnight — and no one is measuring this.
CPAP and kidney function: CPAP treatment for sleep apnea has been associated with improved albuminuria and proteinuria in several studies. However, the CPAP machine itself introduces new variables (see EMF section above). The therapeutic benefit of restored oxygenation is real and significant; the question of whether the device's wireless features should be disabled during use is a separate and addressable one.
Industrial Toxins, Heavy Metals & Environmental Nephrotoxins
The kidney as the body's filter for everything it cannot otherwise eliminate
Because the kidneys filter the entire blood volume approximately every 30 minutes, they are the primary point of accumulation for environmental toxins that enter the body through food, water, air, and skin. Many of the exposures below are present in daily life — in food, tap water, personal care products, and cosmetics — at levels that individually may be subclinical, but that compound over years of simultaneous exposure.
Glyphosate — CKDu (Chronic Kidney Disease of Unknown Etiology)
In Sri Lanka, El Salvador, Nicaragua, and other agricultural regions, a kidney disease epidemic among farmers with no history of diabetes or hypertension has been labeled CKDu — chronic kidney disease of unknown etiology. It is not unknown. The Jayasumana hypothesis, published in multiple peer-reviewed journals and recognized by the AAAS with its Scientific Freedom and Responsibility award (2019), links the epidemic to glyphosate used on crops combined with hard groundwater containing heavy metals.
The mechanism: Glyphosate is a powerful chelator — it binds to minerals including cadmium, arsenic, and lead. In hard water, glyphosate forms stable complexes with these heavy metals. When ingested in that combination, the compound delivers concentrated heavy metals directly to renal tubular cells that would otherwise not have absorbed those metals at the same rate. A WHO study found glyphosate, cadmium, arsenic, and lead in well water in affected areas; 65% of CKDu subjects excreted glyphosate in urine. Subjects who sprayed glyphosate were 4 times more likely to develop CKDu. 96% of CKDu patients had consumed hard groundwater for 5+ years before diagnosis.
Scale: Sri Lanka: 150,000+ affected, estimated 5,000 deaths/year. El Salvador and Nicaragua: more men die of CKDu than from HIV/AIDS, diabetes, and leukemia combined. Both countries banned glyphosate in 2013–2014 specifically due to CKDu. The US has not.
Heavy Metals — Cadmium, Lead, Arsenic, Mercury
All four are direct proximal tubular nephrotoxins via oxidative stress. All four accumulate in the body with chronic low-level exposure. All four are present in daily consumer products at levels that are not regulated to zero.
Cadmium
Mechanism: Accumulates in the renal medulla and S1 proximal tubule segment; causes chronic tubulo-interstitial nephropathy, polyuria, proteinuria, glycosuria, aminoaciduria, phosphate wasting (Fanconi syndrome pattern). Half-life in the kidney: 10–30 years. Damage accumulates long before symptoms appear.
Hidden sources: Cigarette smoke (primary source — 1–3 mcg cadmium per cigarette, all inhaled); contaminated rice and wheat (cadmium-rich phosphate fertilizers); some chocolate; leafy greens grown in contaminated soil; certain cosmetics (lipstick, eye shadow — cadmium used as a colorant); sunflower seeds. Tamara Rubin (Lead Safe Mama) and independent testing have documented cadmium in cosmetics, crayons, and candy at levels not disclosed on labels.
Lead
Mechanism: Tubular toxicity; lead competes with calcium for transport; causes uric acid retention (lead nephropathy presents like gout-CKD); impairs mitochondrial function in tubular cells. Lead stored in bone is mobilized during pregnancy, menopause, and osteoporosis — releasing stored lead into circulation decades after exposure.
Hidden sources: Old paint dust during home renovation (pre-1978 homes); old water pipes and brass fixtures (still present in millions of US homes); some glazed ceramics and imported dishware; certain lipsticks (FDA testing found lead in 400 lipstick products, up to 7.19 ppm); candy wrappers and imported candy (Florida DOH testing documented); spices imported from countries without heavy metal regulations; Ayurvedic supplements. Lead Safe Mama (Tamara Rubin) has published independent XRF testing of thousands of consumer products documenting lead in children's toys, dishes, jewelry, and cosmetics.
Arsenic
Mechanism: Tubular toxicity; oxidative stress; chronic low-level arsenic causes proteinuria, interstitial nephritis, and is associated with increased CKD incidence in populations with contaminated groundwater.
Hidden sources: Groundwater (naturally occurring in many US regions — New England, Midwest, Southwest; well water not regulated by EPA Safe Drinking Water Act); rice and rice products (arsenic-hyperaccumulating crop; brown rice contains more than white); apple and grape juice; some chicken (arsenic used historically in poultry feed); some infant formulas using rice syrup as a sweetener; contaminated soil in agricultural areas near former pesticide sites (lead arsenate was used on orchards until the 1970s — soil contamination persists in former orchard land converted to residential or vegetable farming).
Mercury
Mechanism: Proximal tubular cell accumulation; inhibits tubular reabsorption; disrupts mitochondrial respiration; inorganic mercury in kidneys from amalgam fillings, organic mercury from fish, ethylmercury from thimerosal in vaccines.
Hidden sources: Dental amalgam fillings (release mercury vapor continuously; elevated on chewing, grinding, hot beverages; fillings placed decades ago continue to off-gas); certain skin-lightening creams (mercury used as a bleaching agent — illegal in US but imported products widely available; FDA has documented mercury up to 33,000 ppm in some products); some imported cosmetics; certain eye drops and contact lens solutions (thimerosal still used as a preservative in some formulations); large predatory fish (tuna, swordfish, king mackerel, shark).
Fluoride — Toothpaste, Dental Treatments, and the Cumulative Renal Load
The kidney is the primary route of fluoride excretion, responsible for clearing 50–60% of ingested fluoride within 24 hours in healthy individuals. In CKD, this clearance is impaired — fluoride accumulates in bone and soft tissue. Fluoride at elevated concentrations directly damages renal tubular epithelial cells. Most conversations about fluoride exposure stop at tap water. They should not.
Fluoride toothpaste — daily exposure, twice per day, for life
Standard adult toothpaste: 1,000–1,500 ppm fluoride (1.0–1.5 mg per gram of paste). A full brush application uses approximately 1.5g of paste = 1.5–2.25 mg fluoride applied to the oral mucosa twice daily. Even with thorough rinsing, oral mucosal absorption occurs — particularly with whitening toothpastes, sensitivity formulas, and fluoride rinses designed to have prolonged contact time. Prescription-strength toothpastes (Prevident 5000, Clinpro 5000) contain 5,000 ppm fluoride — 3 to 5 times the standard concentration — and are routinely prescribed to patients with dry mouth, recession, or high cavity risk. They are not prescribed with any mention of kidney fluoride load.
Children: FDA and AAP recommend pea-size amounts (0.25g) for ages 1–6 — but independent studies show children swallow 20–50% of applied toothpaste, depending on age and supervision. A child brushing with standard toothpaste and swallowing 30% ingests ~0.3–0.45 mg fluoride per session, twice daily, in addition to fluoridated water and food sources.
The label: Every fluoride toothpaste sold in the US carries an FDA-mandated Poison Control warning: "If more than used for brushing is accidentally swallowed, get medical help or contact a Poison Control Center right away." This warning appears on every tube and is ignored by virtually every consumer and prescriber.
Professional fluoride varnish — 22,600 ppm, applied at every dental cleaning
Fluoride varnish (5% sodium fluoride = 22,600 ppm) is the standard professional application applied to teeth at most dental cleanings and pediatric dental visits. A standard application uses 0.25–0.5 mL of varnish = approximately 5–11 mg of fluoride painted directly onto tooth surfaces. Patients are told not to eat or drink for 30 minutes. During that window — and in the hours after as the varnish slowly melts off the teeth — the fluoride is swallowed and absorbed. Applied every 3–6 months to children starting at age 1 per the AAP recommendation, and routinely to adults at recall appointments.
Annual exposure from varnish alone: 2 applications/year × 5–11 mg = 10–22 mg fluoride in concentrated dental-application form, in addition to all daily toothpaste and water exposure.
Fluoride gel and foam trays — 12,300 ppm, significant ingestion in children
Acidulated phosphate fluoride (APF) gel and foam — 1.23%, or 12,300 ppm — are applied in dental trays for 3–4 minutes at many dental offices, particularly for children. Studies document that children swallow 30–70% of the gel or foam during tray application due to inability to control salivary flow. At 50% ingestion of a standard tray load, a child may ingest 5–15 mg of fluoride in a single dental visit — a dose that in an adult would approach or exceed the acute minimal risk level. This is applied at every 6-month cleaning. Dentists are not required to disclose the fluoride content to parents before application.
Prescription fluoride supplements — drops and tablets in non-fluoridated areas
Fluoride drops (Luride, Flura-Drops) and chewable tablets are prescribed to children in areas where the water fluoride level is below 0.3 ppm, at doses of 0.25–1 mg/day depending on age. These are swallowed daily, adding to toothpaste and varnish exposure. Prescriptions are often continued for years without revisiting water fluoride content, child's weight, or total daily fluoride load from all sources combined.
The total daily fluoride load — never calculated, never disclosed
A child in a fluoridated water area brushing twice daily with standard toothpaste (swallowing 30%), drinking fluoridated water, eating processed foods made with fluoridated water, and receiving professional varnish twice yearly is exposed to a cumulative fluoride load that is rarely totaled by any clinician. For a CKD patient — adult or child — whose kidneys cannot clear fluoride efficiently, this cumulative daily load becomes a persistent tubular stressor that no one in their care team is measuring or discussing.
Other fluoride sources beyond dental: fluorinated toothpaste for "whitening" (often higher fluoride + hydrogen peroxide); fluoride-containing mouthwashes (ACT, Listerine Total Care — 225 ppm); black and green teas (tea plants hyperaccumulate fluoride from soil — 1–5 mg per cup depending on brewing time and tea variety); grape juice and wine; fluorinated pesticide residues (cryolite) on produce; some processed foods and beverages manufactured with fluoridated municipal water; fluorine-atom-containing pharmaceuticals (fluoroquinolones, many SSRIs, inhaled corticosteroids) that release inorganic fluoride during metabolism.
PFAS — "Forever Chemicals"
Per- and polyfluoroalkyl substances (PFAS) are present in at least 45% of US tap water according to a 2023 USGS study. PFOA and PFOS — the most studied PFAS compounds — are associated with kidney dysfunction, CKD progression, and kidney cancer. A published study found that when PFAS exposure increased by one standard deviation, kidney function at follow-up was 2.4% worse. PFAS are renally cleared very slowly — half-lives of years — meaning they accumulate continuously with ongoing exposure.
Sources: Contaminated municipal water (especially near military bases, airports, and manufacturing facilities); non-stick cookware (Teflon off-gassing accelerated above 260°C/500°F); food packaging (microwave popcorn bags, fast food wrappers, pizza boxes); stain-resistant coatings on carpets and upholstery; some waterproof clothing; certain personal care products (dental floss with PTFE coating, some shampoos and conditioners). PFAS are not removed by standard pitcher or refrigerator filters — requires activated carbon block or reverse osmosis.
Trichloroethylene (TCE) — Industrial Solvent
TCE is a chlorinated solvent used in metal degreasing, dry cleaning, and manufacturing. The US National Toxicology Program classifies it as a known human carcinogen. 12 cohort studies and 7 case-control studies document occupational TCE exposure as a cause of renal cell carcinoma. Genotoxic metabolites from TCE biotransformation target kidney tissue specifically. TCE is among the most common contaminants at Superfund sites — groundwater contamination in residential areas near former industrial sites affects communities who may not know their well water carries this exposure. TCE co-exposure with arsenic (common at the same Superfund sites) compounds kidney cancer risk.
Ochratoxin A — Mold Mycotoxin in Grain, Coffee, Wine, and Spices
Ochratoxin A (OTA) is produced by Aspergillus and Penicillium molds that colonize stored grains, coffee beans, grapes, dried fruits, spices, cocoa, and animal products (pork, poultry, dairy). It is nephrotoxic, immunotoxic, neurotoxic, and carcinogenic. OTA accumulates in renal proximal tubular cells, causing chronic interstitial nephropathy and is linked to Balkan endemic nephropathy — the same geographic kidney disease pattern that was later also linked to aristolochic acid. Some researchers consider OTA the primary driver of Balkan endemic nephropathy rather than aristolochic acid, or a co-factor alongside it.
Inhalation route: OTA is also nephrotoxic via inhalation — relevant to people living or working in water-damaged buildings with visible or hidden mold. A review in the Journal of Renal Nutrition documented focal segmental glomerulosclerosis (FSGS) in patients with documented ochratoxin A inhalational exposure.
Sources: Conventionally stored grain products (bread, cereal, pasta, crackers — OTA survives baking); commercial coffee (especially ground coffee stored in humid conditions); commercial wine; raisins and dried figs; some spices including paprika and black pepper; pork from conventionally raised animals fed contaminated grain. Organic farming practices and better grain storage significantly reduce OTA levels.
Hidden Heavy Metal Exposure in Consumer Products — The Undisclosed Toxic Load
Heavy metals accumulate silently in kidney tissue over years. They are not always coming from obvious industrial sources. Tamara Rubin (Lead Safe Mama) has conducted independent XRF (X-ray fluorescence) testing on thousands of consumer products and documented lead, cadmium, arsenic, and mercury in products that are not required to disclose these metals on their labels.
The kidney burden context: No single exposure from the above list is typically enough to cause acute kidney injury. The clinical question is cumulative: a person using lead-containing lipstick daily, eating rice and conventionally stored grain products, living in a pre-1978 home, drinking from older pipes, using fluoridated toothpaste, taking a fluoroquinolone for a UTI, and receiving annual flu shots from multi-dose thimerosal-containing vials is not experiencing one toxin exposure — they are experiencing 6 or 8 or 10 simultaneously, every day, for years. The kidney filters all of it. The nephrology workup evaluates none of it.
Plastics, Fortified Foods, Synthetic Vitamins & Water Quality
Daily inputs that compound the kidney's filtration burden invisibly
Plastic Water Bottles — BPA, BPS, Phthalates, and Microplastics
Bisphenol A (BPA) and its replacement Bisphenol S (BPS) — used in hard plastic bottles, food can liners, and thermal receipt paper — are endocrine disruptors that are renally cleared. Studies show BPA and BPS accelerate renal fibrosis and reduce GFR in animal models; epidemiological data shows higher urinary BPA associated with increased CKD risk and proteinuria in humans. "BPA-free" labeling does not mean bisphenol-free — BPS and BPF, used as replacements, demonstrate similar or greater estrogenic activity and similar renal excretion demands.
Phthalates — plasticizers in soft plastics, food wrapping, and personal care products — are also renally cleared and associated with tubular injury markers in epidemiological studies. Urinary phthalate metabolites are correlated with reduced kidney function in multiple population studies.
Microplastics: Now documented in human kidney tissue, blood, placenta, and lung. The long-term effect of plastic particle accumulation in renal tubular cells is not yet established — because the exposure is so recent at the scale currently occurring. Bottled water contains significantly more microplastics than tap water; heating food in plastic containers dramatically increases plastic leaching. Glass and stainless steel are the only containers that do not leach.
Fortified Foods & Synthetic Vitamins — The Fortification Paradox
Food fortification began as a targeted public health intervention — iodized salt to prevent goiter (1924), vitamin D in milk to prevent rickets (1930s), B vitamins in enriched flour to prevent pellagra and beriberi (1941), folic acid in grain products to reduce neural tube defects (1998). Each intervention addressed a real deficiency disease. The problem that emerged: synthetic forms ≠ food forms; individual genetic variation in conversion enzymes was not accounted for; and the population-wide mandatory daily exposure across decades was never studied for cumulative effects. A patient eating fortified cereal with fortified milk and fortified OJ while taking a prenatal vitamin and a multivitamin is receiving simultaneous multi-gram doses of synthetic nutrients across multiple forms — none of it tracked, integrated, or disclosed by any clinician.
Folic acid — mandatory in all enriched grain products since 1998
Folic acid is the oxidized synthetic form of folate. It requires enzymatic conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to become the biologically active 5-methyltetrahydrofolate (5-MTHF). Approximately 40–60% of the population carries MTHFR variants (C677T, A1298C) that reduce conversion capacity by 30–70%. In these individuals, unconverted folic acid (UMFA) accumulates in plasma with every fortified meal.
Where it goes: UMFA is cleared renally. In CKD patients who cannot clear it efficiently, it accumulates. High circulating UMFA is associated with immune dysregulation (NK cell suppression), masks vitamin B12 deficiency (a dangerous clinical blind spot — B12 deficiency can cause irreversible neurological damage while folate status appears adequate), and in some research is associated with accelerated tumor growth in existing cancers.
Where it hides: Every slice of commercial bread, every serving of pasta, every bowl of cereal, every tortilla, every cracker, every packaged grain product — plus most prenatal vitamins, multivitamins, and "fortified" beverages. It is essentially unavoidable in a standard Western diet. The food-form alternative — whole food folate from leafy greens, legumes, liver — does not cause UMFA accumulation because it enters the metabolic pathway at a different point.
Vitamin D — added to dairy since the 1930s, now in nearly everything
Vitamin D2 (ergocalciferol) is the fungal-derived synthetic form added to many plant-based milks, OJ, and some cereals. Vitamin D3 (cholecalciferol) is added to dairy. Standard fortification: 400 IU per 8 oz serving of milk — but a person drinking 2 glasses of milk daily, eating fortified cereal, drinking fortified OJ, and taking a multivitamin is receiving 1,600–3,000+ IU from food alone, before any supplements. This compounds with supplement intake — which is frequently an additional 2,000–5,000 IU — bringing total daily D to levels that, over months and years, create the soft tissue and tubular calcification detailed earlier in this tab.
No feedback regulation: Sunlight-driven D3 production in skin stops automatically when enough is produced — the melanin pathway provides physiological feedback. Oral D — whether from supplements or fortified foods — bypasses this mechanism entirely. The body cannot down-regulate intake from food or pills. The kidney is responsible for activating and regulating D, and in CKD this regulatory capacity is already impaired.
D2 vs. D3: Ergocalciferol (D2) in many fortified foods has shorter half-life and lower potency than D3, but raises 25-OH D levels used in lab testing — creating the appearance of adequate status while the body's ability to regulate it differs from food-derived D. Infant formulas add D at levels calibrated for bottle-fed infants; when infants also receive sunlight and mothers take prenatal vitamins, cumulative exposure is not assessed.
Vitamin A — retinyl palmitate added to low-fat dairy and fortified foods
Preformed vitamin A (retinyl palmitate) is added to skim and low-fat milk to replace the fat-soluble vitamins lost when milkfat is removed. It is also in most multivitamins, prenatal vitamins, fortified cereals, and some margarines. Preformed vitamin A — unlike beta-carotene, which the body converts on demand — accumulates directly in the liver. Vitamin A toxicity (hypervitaminosis A) is the most commonly documented fat-soluble vitamin toxicity.
Kidney-specific effects of vitamin A toxicity: Renal tubular acidosis has been documented in chronic vitamin A toxicity. Hypervitaminosis A also causes elevated intracranial pressure, hepatic fibrosis, bone loss with fracture risk, and skin changes. The cumulative intake from fortified skim milk daily + multivitamin + prenatal vitamin + some fortified cereals places many people — particularly pregnant women taking prenatal vitamins alongside eating fortified foods — in ranges that approach or exceed the Tolerable Upper Intake Level (3,000 mcg RAE/day) without awareness.
Liver-food interaction: Chicken liver, beef liver, and fish liver oils are extremely high in preformed vitamin A. A person eating liver weekly while drinking fortified skim milk and taking a prenatal vitamin containing retinyl palmitate may be chronically exceeding safe intake — with the kidneys bearing the clearance burden of the metabolic consequences.
Iron — ferrous sulfate and reduced iron in enriched grain products since 1941
Ferrous sulfate and "reduced iron" (elemental iron powder) are the forms added to bread, cereal, pasta, and rice. Both are minimally bioavailable — the gut absorbs perhaps 2–10% of the added iron depending on the individual's iron status and gut chemistry. The remaining 90–98% passes through the intestine, where it becomes a pro-oxidant: unabsorbed iron generates reactive oxygen species in the gut lumen, feeds pathogenic bacteria over beneficial microbiota, drives intestinal inflammation, and increases gut permeability.
The ferritin connection: Chronic gut inflammation from unabsorbed fortification iron elevates systemic inflammatory markers — including ferritin. Ferritin elevation from this pathway is then used to justify iron infusions in CKD patients, completing a cycle in which fortification iron drives inflammation that raises ferritin that triggers IV iron administration that causes tissue iron overload. The original driver — daily unabsorbed fortification iron — is never identified.
B vitamins (thiamine, riboflavin, niacin, B6) — enrichment since 1941
Niacin (nicotinic acid): Added to all enriched grains. At high doses — reached by people eating multiple fortified foods plus taking niacin supplements — causes hepatotoxicity (especially sustained-release forms), flushing, hyperglycemia, and elevated uric acid. Elevated uric acid from excess niacin is a direct contributor to urate nephropathy. Energy drinks often contain B3 at 100–200% DV per serving, on top of food fortification.
Synthetic B6 (pyridoxine hydrochloride): Added to cereals, nutrition bars, and most multivitamins at doses that individually appear safe. However, chronic excess pyridoxine — consistently above ~50 mg/day from all sources combined — causes peripheral sensory neuropathy. B6 content in fortified foods is not labeled in a way that allows consumers to track their total daily intake across all sources.
B12 (cyanocobalamin vs. methylcobalamin): The synthetic form added to most fortified foods and supplements is cyanocobalamin — which must be converted to methylcobalamin or adenosylcobalamin for biological activity. The conversion releases a cyanide molecule (very small, normally cleared; but relevant in people with impaired clearance, smokers, and CKD patients). Methylcobalamin is the food-form-equivalent and does not require this conversion. The distinction is not communicated on labels.
Iodine — iodized salt and the thyroid-kidney connection
Iodized salt (since 1924) effectively eliminated goiter. However, excess iodine — from iodized salt combined with iodine in seaweed products, certain multivitamins, and some thyroid supplements — triggers the Wolff-Chaikoff effect in susceptible individuals: transient thyroid suppression followed by potential hypothyroidism or hyperthyroidism in those with pre-existing thyroid abnormalities.
Thyroid-kidney link: Thyroid hormones directly regulate renal hemodynamics — they maintain GFR, renal blood flow, and tubular transport function. Hypothyroidism (from iodine overload, autoimmune thyroid disease, or any other cause) reduces GFR and causes fluid and sodium retention — producing a CKD-like picture that is sometimes attributed to primary kidney disease when the thyroid is the driver. In patients with both thyroid dysfunction and CKD, the thyroid component of the kidney picture is frequently underaddressed.
Calcium — added to plant milks, OJ, and fortified foods as calcium carbonate
Plant-based milks (oat, almond, soy, rice) are fortified with calcium carbonate to approximate the calcium content of dairy. Calcium carbonate is the same compound used in antacid medications (Tums, Rolaids). When consumed daily in plant milks, OJ, and fortified cereals — alongside calcium supplements and dairy — the cumulative calcium carbonate load contributes to the same vascular calcification and milk-alkali syndrome risk described in the antacid section. This is particularly relevant in CKD patients who have been told to "get more calcium" and switched to plant milks not realizing those milks contain the same calcium form as antacids. Food-form calcium from bone broth, dairy (without fortification), and leafy greens enters a different absorption pathway with more physiological regulation.
Hidden fortification — it is not just breakfast cereal
Fortification extends far beyond the obvious sources. The following contain significant synthetic nutrient loads that are rarely considered when assessing a patient's total daily intake:
Excipient accumulation in supplements: Most supplements contain synthetic dyes, titanium dioxide (TiO₂ — banned in the EU as of 2022 but still used in the US), magnesium stearate, polyethylene glycol coatings, silicon dioxide, carrageenan, and other fillers that are renally cleared. The person taking 10–15 supplements daily — which is common in the wellness-oriented CKD patient — is delivering a continuous stream of non-therapeutic compounds to kidneys that are already struggling. No one quantifies this load or asks about it in a nephrology appointment.
Water Quality — What Happens When the Water Itself Harms the Kidneys
The kidneys require adequate mineral-containing water to maintain tubular cell function, filter properly, and prevent urine from becoming so concentrated it promotes crystal formation. What the patient drinks — and what minerals (or anti-nutrients) are in it — matters directly to kidney health.
Reverse osmosis (RO) water — demineralized, acidic
RO filtration removes virtually all minerals — including magnesium, calcium, and potassium that the kidney uses for tubular function and electrolyte regulation. Long-term consumption of demineralized water forces the body to leach minerals from bone to buffer the water's acidity and compensate for the missing electrolytes. The WHO has documented health concerns with long-term demineralized water consumption: decreased urine output, electrolyte imbalance, and increased risk of calcium and magnesium deficiency. For a CKD patient whose mineral regulation is already impaired, removing the mineral content of their primary fluid source compounds the deficit. RO water without remineralization is not appropriate long-term hydration — it is closer to a solvent than a food.
Alkaline / ionized / Kangen water — false pH premise, no mineral benefit
Ionized alkaline water machines (including Kangen) electrolyze tap water to produce a higher pH. The premise — that drinking alkaline water changes the body's pH — is physiologically incorrect. The stomach immediately acidifies any water consumed to below pH 3.0 for digestion. The kidneys regulate blood pH within a narrow range (7.35–7.45) regardless of what is consumed; this is not influenced by water pH. Alkaline water machines cost $2,000–$5,000 and do not produce water with any demonstrable kidney benefit. They also do not filter contaminants — if the tap water contains lead, PFAS, or pharmaceuticals, ionized water contains them too. The only benefit is hydration — which any clean water provides.
Municipally treated tap water — chlorine, chloramines, pharmaceuticals, fluoride
Standard municipal water treatment uses chlorine or chloramines (chlorine + ammonia) as disinfectants. Chloramines are not removed by standard pitcher filters, boiling, or standing; they require catalytic carbon filtration. Pharmaceutical residues — including hormones, antibiotics, anticonvulsants, and antidepressants — pass through wastewater treatment and return to the water supply; these are not regulated under the Safe Drinking Water Act. Fluoride, added at 0.7 ppm, accumulates in CKD patients who cannot clear it efficiently. For kidney patients, the ideal water is natural spring water (tested — some springs are contaminated), or filtered water through a whole-house carbon system that removes chloramines and organics without stripping minerals.
Chronic dehydration — the most overlooked kidney stressor
The kidney cannot concentrate urine beyond the body's dehydration state. Chronically low fluid intake — common in elderly patients, people in hot climates, and caffeine or alcohol consumers — produces continuously concentrated urine that increases crystal formation risk and reduces the kidney's ability to flush tubular debris. Urine should be pale yellow. Dark urine in the absence of B vitamins or medication pigmentation is a dehydration signal. This is one of the simplest and most reversible kidney stressors — and it is rarely assessed in a nephrology visit beyond a one-line question.
Emotions & the Kidneys
The physiological pathway is established — and the mind-body tradition has mapped this territory for decades
The connection between emotional state and kidney function is not metaphor. Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis, producing sustained cortisol elevation. Cortisol stimulates the renin-angiotensin-aldosterone system (RAAS) — the same system that ACE inhibitors and ARBs are designed to suppress. Chronic RAAS activation causes renal vasoconstriction, glomerular hypertension, and progressive nephron loss. A body that lives in sustained fear, shame, or unresolved grief is running the same biological cascade as a body given a drug that raises angiotensin II — just silently, from the inside, for years.
Chronic stress also impairs the nocturnal blood pressure dip that allows kidney repair overnight. Non-dippers — those whose blood pressure does not fall 10–20% during sleep — have significantly faster CKD progression. Emotional dysregulation, trauma, and hypervigilance are among the most reliably documented contributors to the non-dipper pattern. This is nephrology. It simply is not presented that way.
TCM and the mind-body tradition
In Traditional Chinese Medicine, the kidneys are governed by fear. The kidney system — which includes the adrenal glands in this framework — is considered the root of vitality, the storehouse of ancestral energy, and the organ most affected by chronic existential fear: fear about survival, fear of not being enough, fear of the future. When that fear is chronic and unaddressed, the kidney system is the first to be depleted.
The modern HPA axis / RAAS cascade describes the same pathway in biochemical terms. Fear activates the adrenals. Sustained adrenal activation depletes the system that governs kidney filtration, blood pressure regulation, and fluid balance. These are not parallel systems — they are the same system described in different languages.
Kidney disease and failure — criticism, shame, the fear of having failed
In the mind-body tradition documented by Alice Steadman, Louise Hay, and others working independently across decades, kidney disease is consistently associated with long-standing self-criticism, a deep sense of shame or disappointment in oneself, and the fear of being seen as a failure. The kidneys filter the blood — energetically, they are understood to filter what we judge as impure or unworthy in ourselves. When that internal criticism is chronic and relentless, the organ most associated with filtration and purification carries the physiological load. The HPA pathway makes this a mechanism, not just a metaphor: shame and chronic self-judgment are among the most reliably documented activators of sustained cortisol and sympathetic nervous system tone.
Kidney stones — resentment that has crystallized
Kidney stones in the mind-body tradition map to anger and resentment that has accumulated over time — grievances that were never addressed, hardening by suppression into a physical form. Physiologically, chronic sympathetic activation and RAAS engagement alter urine calcium and uric acid excretion in ways that increase stone formation risk. The emotional framing and the biochemical framing are not in conflict. They describe different entry points to the same process.
This dimension belongs in the conversation
Nephrology appointments evaluate eGFR, creatinine, BUN, and urinalysis. They do not ask about sustained fear, unresolved shame, relationship patterns, or how long the patient has felt like a burden or a disappointment. They do not connect the patient's history of carrying everyone else's weight to the organ system that governs fluid regulation and survival physiology.
This is not a replacement for the pharmaceutical, environmental, and nutritional inputs covered elsewhere in this tab. It is an additional layer — one that the patient is uniquely positioned to address, and that no prescription manages. The Emotions & Disease database includes specific entries for kidney disease, kidney stones, and the urinary system.
The pattern worth recognizing
Kidney disease rarely has a single cause
In most patients who reach ESRD, the trajectory involved multiple simultaneous inputs over years — often a combination of pharmaceutical nephrotoxins, contrast exposures, dehydration, inflammatory burden from iron overload, calcification from supplement and fortified food accumulation, sleep disruption, environmental chemical and heavy metal loading, and plastic and synthetic additive accumulation. No single cause produces ESRD quickly in most people. Multiple causes compound each other, silently, over a decade or more.
The nephrology appointment evaluates creatinine, BUN, eGFR, and urinalysis. It does not evaluate what the patient is drinking, eating, breathing, or absorbing through their skin. It does not ask about supplement load, water source, heavy metal exposure, EMF environment, sleep quality, fluoride burden, vaccine history, or the chronic emotional patterns — fear, shame, sustained grief — that activate the same hormonal cascade as the drugs the patient is already taking. All of these contribute to the total load on an organ that filters everything.
The inverse of this is also true: when the inputs are identified and systematically reduced, the kidney — if it still has recoverable nephrons — responds. The clinical observation of eGFR 18 to 52 in three months is not exceptional biology. It is what happens when the load on a recoverable organ is sufficiently cleared. The question that must precede any dialysis conversation is not "what type of dialysis?" — it is "have we identified and removed what has been damaging this patient's kidneys?" If that conversation has not happened, informed consent has not happened.